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Preterm birth (PTB) is a leading cause of mortality and disease burden globally; 
however, determinants of human parturition remain largely uncharacterized, making 
prediction and prevention of difficult. Genetic studies are one way in which we can 
attempt to better understand this disorder.  
We first sought to develop a model for the genetic influences on PTB to facilitate 
gene discovery. Study of standard measures of familial aggregation, the sibling risk ratio 
and the sibling-sibling odds ratio, and segregation analyses of gestational age, a 
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quantitative proxy for preterm birth, lend support to a genetic component contributing to 
birth timing, since preterm deliveries cluster in families and models in which 
environmental factors alone contribute to gestational age are strongly rejected. Analyses 
of gestational age attributed to the infant support a model in which mother’s genome 
and/or maternally-inherited genes acting in the fetus are largely responsible for birth 
timing.  
We also aimed to discover specific genes associated with PTB by screening genes 
selected based on an evolutionary-motivated filter, rather than known parturition 
physiology. Because humans are born developmentally less mature than other mammals, 
birth timing mechanisms may differ between humans and model organisms that have 
been typically studied; as a result, we screened 150 genes, selected because of their rapid 
evolution along the human lineage. A screen of over 8000 SNPs in 165 Finnish preterm 
and 163 control mothers identified an enrichment of variants in FSHR associated with 
PTB and prompted further study of the gene. Additionally, PLA2G4C, identified as the 
gene with the most statistically significant evidence for rapid evolution that was also 
included in a list of preterm birth candidate genes, was examined further. Three SNPs in 
PLA2G4C and one SNP in FSHR were statistically significant across populations after 
multiple testing corrections. Additional work to identify variants in these genes with 
functional effects was also initiated, including comparisons of prostaglandin metabolite 
levels among genotype classes for significantly associated SNPs in PLA2G4C and 
sequencing of FSHR to identify functional coding variants. Together, these experiments 
better characterize the nature of genetic influences on PTB and support the role of 
PLA2G4C and FSHR in PTB.  
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 Chapter 1: Introduction
*
 
Clinical aspects of preterm birth (PTB) 
Human parturition typically occurs between 37-42 weeks of gestation, with 40 
weeks being the most common time of delivery (Figure 1.1). Deliveries before 37 weeks 
are designated as “preterm” births by the World Health Organization [1] and represent an 
important public health concern. Approximately one-third of infant deaths are attributable 
to prematurity [2]. Preterm infants also have an increased risk of serious health problems, 
such as respiratory illness, blindness and cerebral palsy [3]. Moreover, the severity and 
incidence of these problems worsen with decreasing gestational age [4].  
A variety of subtypes of PTB can be described. For example, preterm births may 
be spontaneous or medically indicated. For 20-30% preterm births, women are delivered 
early to minimize complications from maternal conditions, like preeclampsia, or fetal 
distress [4]. However, most preterm births result from spontaneous preterm labor or 
preterm premature rupture of membranes (PPROM) [4]. Preterm labor or PPROM may 
arise in response to various stimuli, such as damage to the placental unit, intrauterine 
infection or changes in cervical length, but the mechanisms by which these processes are 
initiated are unknown. Additionally, early births of multiple gestations, which are 
generally delivered earlier than singletons, may occur by different mechanisms than 
singleton PTB. Hence, considerable heterogeneity in etiology may exist among various 
subgroups of PTB and warrants careful consideration of phenotype in studies of PTB.  
PTB is common, with rates consistently rising in recent decades. In 2006, 12.8% 
of births in the United States occurred before 37 weeks, a 21% increase since 1990 [5]. 
                                                 
*
 This chapter is adapted from: Plunkett J & Muglia LJ. (2008) Genetic Contributions to PTB: 
Implications from Epidemiological and Genetic Association Studies. Ann Med., 40(3):167-95. 
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 While the recent rise in multiple births, which are generally delivered earlier than 
singletons, contributes to this increase, the rate among singleton gestations has risen 13% 
since 1990 and is now 11.1%. Among singleton PTB, late-preterm births (34-36 weeks) 
account for all of the increase, with essentially no change in the rate of births <34 weeks 
during this period. Importantly, cesarean-delivery rates have also increased since 1990, 
such that medically-indicated PTB may represent a greater portion of the increase in 
overall PTB rate. Consequently, distinguishing spontaneous from medically-indicated 
PTB may be important in identifying risk factors for this condition. 
Of note, rates differ among racial groups. Blacks experience approximately twice 
the rate of PTB than that of Whites. The highest PTB rates are observed when both 
parents are Black and remain higher when one parent is Black, whether that parent is the 
mother or father [6; 7]. According to a study by Goldenberg and colleagues [8], these 
racial disparities are not explained entirely by measured medical and environmental risk 
factors, such as smoking, hypertension, education level or socioeconomic status, 
suggesting that other differences among races, such as genetic ancestry, contribute to the 
disorder. As a result, careful consideration of important differences in social, cultural and 
biological factors among races also are important in studies of PTB risk. 
Motivation for studying genetics  
While a number of risk factors have been identified, accurate prediction and 
prevention of PTB are difficult [4]. For example, biomarkers, such as serum protein 
concentrations of IL-6, IL-8, TNF  or relaxin, while strong predictors of PTB, may not 
be useful in large low-risk populations [9]. One problem may be that such markers vary 
2
 over time or among individuals, making it difficult to determine levels at which risk for 
PTB is increased.  
In contrast, genetic factors are stable over time and therefore may be better 
predictors of risk. As a result, genetic studies may identify markers which more 
accurately predict PTB than currently known risk factors. Genetic studies may also 
identify novel proteins and/or pathways involved in the disorder. This new information 
will augment our general understanding of parturition and provide new targets for drug 
therapies, potentially improving both prevention and treatment of PTB.  
 
Evidence for genetic influences on birth timing 
Birth timing across pregnancies in the same woman 
A wealth of evidence suggests that genetics are important in birth timing. For 
example, both preterm and postterm births tend to recur in mothers [10-15]. Moreover, 
the most likely age for a recurrent PTB is same week as the first PTB [12; 16; 17], 
suggesting that factors that are stable over time, such as genetics, affect birth timing. 
Birth timing trends among family members 
Familial trends for birth timing also suggest that genetics influence this trait. 
Women who are born preterm are more likely to have a preterm delivery themselves [18], 
indicating that mothers and their daughters share risk. Sisters of women who have had a 
preterm delivery also have an increased risk for preterm delivery [15]. Due to the nature 
of family studies, environmental factors shared between mothers and daughters or 
between sisters cannot be untangled from genetic influences. As a result, it is difficult to 
3
 determine the relative importance of genetic versus environmental factors from these 
studies alone.  
Partitioning variance in birth timing into genetic versus environmental components 
In contrast to family studies, twin studies measure the relative importance of 
genes in overall trait variance within a population. By comparing concordance rates 
between monozygotic and dizygotic twins, which share 100% and approximately 50% of 
their genes, respectively, one can model the genetic and environmental factors that 
influence a trait. Such studies indicate that genes account for about 30% of variation in 
preterm delivery [19; 20] and child’s gestational age as continuous trait [19; 21], when 
the mother is considered the proband of a delivery.  
A similar method was used to estimate the influence of maternal and fetal genetic 
factors by Lunde and colleagues [22]. Comparing concordance rates among full and half 
siblings for gestation age, the authors estimated that 11% of variation for this trait is due 
to fetal genetic factors and 14% of variation is due to maternal genetic factors [22]. Such 
comparisons use the degree of genetic relatedness (on average 50% for full siblings and 
25% for half siblings) and trait concordance to estimate the relative importance of genetic 
versus environmental factors. Because siblings that are not monozygotic twins display 
some variability in their percent genetic identity and may differ in important dominance 
or interactive genetic effects, these estimates are more difficult to make using non-twin 
siblings. Despite the limitations in estimating the heritability, each study suggests that 
genetics play an important role in PTB. 
Another approach to separating genetic and environmental factors is the 
coefficient of kinship. This measure depicts the degree of genetic relatedness within a 
4
 population. Ward and colleagues [23] used this measure to examine genetic influences on 
PTB in a Utah population. The Utah population from which the families were drawn was 
established by 10,000 people who moved to the state to establish the Mormon religion 
[23]. Because Mormons are discouraged from using alcohol or tobacco and have low 
rates of substance abuse and sexually-transmitted diseases, this population may represent 
individuals with relatively few environmental risk factors for PTB [23]. As a result, 
detecting genetic effects may be easier in this cohort of Utah preterm families. In this 
study, Ward and colleagues found that families with preterm deliveries had a 
significantly lower coefficient of kinship than controls [23], indicating that these families 
are more closely genetically-related than control families. This evidence suggests that the 
increased rate of PTB in these families can be explained by genetic factors. It is important 
to note that the authors of this study did not report the relative abundance of any 
environmental risk factors for PTB in the two populations. It is possible that one or more 
important environmental risk factors differ between these groups, in addition to genetic 
relatedness. Hence, the results of Ward et al. [23] support the significance of genetics in 
PTB, but do not address their relative importance compared to known environmental risk 
factors. 
Mendelian disorders 
Certain Mendelian disorders are associated with PTB, further supporting genetic 
effects on birth timing. Ehlers-Danlos Syndrome (EDS) represents a diverse group of 
Mendelian disorders affecting connective tissue, primarily inherited in an autosomal 
dominant manner [24]. Women with vascular EDS have an increased risk of delivering 
preterm, primarily due to PPROM [24]. Since this disorder is inherited in an autosomal 
5
 dominant pattern, there is a 50% chance the fetus has inherited the disorder, making it 
less clear whether the mother’s or infant’s genome contributes to the increase in PPROM 
risk. 
Possible role of fetal genome in birth timing 
Several lines of evidence further suggest that fetal genetic effects may influence 
birth timing. First, fetal genes that are paternally imprinted mainly control placental and 
fetal membrane growth [25]. Because the placenta and fetal membranes likely play a role 
in PTB, fetal genes controlling these tissues may also contribute. Additionally, several 
studies suggest that paternity affects risk for the disorder. For example, several studies 
indicate that partner changes between pregnancies reduced risk of PTB [26; 27]; 
however, changes in paternity may reflect association with long interpregnancy intervals 
rather than paternity effects per se. Paternal race also has been associated with PTB risk 
[6; 7], suggesting that fetal race may influence birth timing. However, father’s family 
history of PTB has been shown to have only a weak association with risk. While an early 
study of a Norwegian birth registry demonstrated a correlation between fathers’ and 
children’s gestational ages [28], a more recent and extensive study of this registry 
suggested fathers contributed little to no risk to preterm delivery risk [29]. Similarly, 
recent studies [21; 30] suggested that paternal genetics contributed little to gestational 
age, but could not refute the possible role of maternally-inherited genes expressed in the 
fetus. Hence, while paternally-inherited genes may contribute little to PTB or other 
disorders, maternally-inherited genes expressed in the fetus may still be important. 
Together, these data suggests that the fetal genome may contribute to birth timing, 
motivating further study defining the infant as the proband.  
6
  
Complexity of genetic effects on birth timing 
There is increasing evidence that PTB can be conceptualized as a common, 
complex disorder. In contrast to Mendelian disorders in which alterations of a single gene 
can lead to disease, complex diseases are influenced by a variety of factors, none 
necessary and sufficient to cause the disorder itself. As a result, there is not a direct 
relationship between genotypes and phenotypes [31]. These disorders likely depend on a 
number of interacting factors, including genetic, epigenetic and environmental risk 
factors[31]. Modeling procedures used by twin studies suggest that additive genetic 
factors and environmental risk factors that are not shared among siblings both influence 
PTB [19; 20; 32]. Additionally, interactions between genes [33; 34] have been associated 
with PTB risk. Several studies suggest that gene-environment interactions, such as 
interactions between inflammatory gene risk alleles and bacterial infections [35-37], also 
influence the disorder. Together, these studies imply that the etiology of PTB likely 
involves genetic as well as environmental factors in complex interactions. 
In addition to the complexity of genetic effects described above, several issues 
complicate how investigators think about the disorder. As mentioned above, it is not clear 
whether the mother or infant from a preterm delivery should be considered the proband. 
As a result, it is not clear which individual’s DNA should be interrogated. Additionally, 
preterm delivery as a trait can be thought of in two ways. First, PTB can be thought of as 
discrete, resulting from genetic factors that lead to either term or early delivery. 
Alternatively, gestational age can be thought of as a quantitative trait, with preterm ages 
as extremely low values; hence, genetic effects may be quantitative trait loci (QTLs) that 
7
 influence the value of gestational age in both term and preterm deliveries. As disease 
models shape how one approaches identifying genes, it is important to consider the 
uncertainty about how to conceptualize PTB when evaluating various approaches taken 
to study this trait.  
 
Identifying specific genes associated with PTB 
Functional candidate gene studies have identified few genes consistently associated 
with PTB 
Candidate genes in a variety of pathways believed to be important in parturition 
have been tested with mixed results (summary in Table 1.1). Few positive association 
findings for PTB have been consistent. To illustrate, for TNF, the most extensively 
studied gene, 11 studies report major effects of the gene[34; 36; 38-46]; yet, 13 others 
report no major effects of the gene [35; 47-56], including a meta-analysis of 7 studies 
[51]. Similarly, IL1RN was associated in 4 studies [57-60], but not in another 6 [39; 46; 
53; 56; 61]. One possible explanation may be that some polymorphisms are significant 
only in the context of a particular environmental factor, such as infection. For example, 
IL6 has been associated in 2 studies without considering environmental influences [62; 
63], associated in another 2 studies only in the context of infection [35; 37], associated in 
another study only in interaction with other genes [41], and not associated in an 
additional 10 studies [34; 39; 42; 46; 53; 54; 56; 64; 65].  
A number of problems in previous studies’ design may limit their ability to detect 
true genetic effects. Most of these studies have been underpowered, because of small 
sample sizes and/or incomplete sampling of genetic variation in a gene of interest. 
8
 Phenotypic heterogeneity also may confound many studies’ results, as most consist of 
mothers and/or children collected using a variety of phenotype definitions that may have 
different etiologies. In addition, genetic etiologies may differ across ethnic groups, since 
pregnancies in which either the mother or father is Black are at increased risk for preterm 
delivery, regardless of which parent is Black; however, few studies have included 
analyses separately by race or attempted to correct for possible population substructure, 
further questioning the validity of many genes associated to date. Moreover, no genetic 
model has been identified for PTB to suggest what nature of genetic effects is expected, 
limiting investigators’ ability to appropriately design such studies. This proposal 
considers such issues to better identify PTB genes. 
Alternative approaches 
A variety of alternative genetic approaches may be undertaken to identify specific 
genes involved in PTB. For example, unbiased genome-wide screens, such as the screen 
conducted on a Danish cohort as part of the National Institutes of Health Gene 
Environment Association Studies (GENEVA) program, may identify novel genes and 
pathways. Additionally, non-additive genetic effects, such as copy number or structural 
variation, may be important avenues for future research. Such approaches may enable 
investigators to identify novel genes and pathways involved in birth timing with 
important clinical applications. 
 
Objectives of dissertation 
The etiology of PTB is complex and likely involves both genetic and 
environmental risk factors. A variety of evidence supports genetic influences on PTB, yet 
9
 few specific genes have been associated with PTB. Developing a model for the genetic 
influences on PTB may facilitate gene discovery. As little work had been done to 
systematically identify a genetic model for PTB, we used sibling risk estimates and 
segregation analyses to identify one. Another method to facilitate discovery of specific 
genes associated with PTB is using a priori methods. Using information from 
comparative genomic studies, we conducted a screen of genes minimally biased by our 
current understanding of parturition to identify novel PTB genes. In order to validate our 
findings, we replicated genes identified in this screen in additional populations. Of note, 
genes encoding the follicle-stimulating hormone receptor, FSHR, and a phospholipase, 
PLA2G4C, showed evidence of association across populations and was investigated 
further. Together, these experiments better characterize the nature of genetic influences 
on PTB and provide evidence for novel genes involved in this disorder. 
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Table 1.1: Summary of candidate gene association studies’ findings as of May 2010. 
 
Gene 
Symbol 
Gene Name Number 
of 
Studies 
Studies reporting 
positive findings 
ABCA1 ATP-binding cassette, sub-family A, member 1 1 0 
ACE angiotensin I converting enzyme  1  7 1 
ADD1 adducin 1 (alpha) 2 0 
ADH1B alcohol dehydrogenase 1B  4 0 
ADH1C alcohol dehydrogenase 1c 5 0 
ADRB2 adrenergic, beta-2, receptor, surface  8 3 
AGT angiotensinogen 3 2 
AGTR1 angiotensin II receptor, type 1 2 0 
ALOX5AP arachidonate 5-lipoxygenase-activating protein  1 0 
ANXA5 annexin A5  1 0 
APOA1 apolipoprotein A-I  1 0 
APOA4 apolipoprotein A-4 1 0 
APOA5 apolipoprotein A-5 1 0 
APOB apolipoprotein B 1 0 
APOC2 apolipoprotein C2 1 0 
APOC3 apolipoprotein C3 1 0 
APOE apolipoprotein E 1 0 
BHMT betaine-homocysteine methyltransferase  1 0 
CBS cystathionine-beta-synthase  5 1 
CCL2 chemokine (C-C motif) ligand 2  4 0 
CCL3 chemokine (C-C motif) ligand 3 4 0 
CCL8 chemokine (C-C motif) ligand 8 4 0 
CD14 monocyte differentiation antigen CD14 5 1 
CETP cholesteryl ester transfer protein, plasma 1 0 
COL1A1 collagen, type I, alpha 1  3 0 
COL1A2 collagen, type I, alpha 2 3 0 
COL3A1 collagen, type 3, alpha 1 3 0 
COL5A1 collagen, type 5, alpha 1 4 0 
COL5A2 collagen, type 5, alpha 2 4 0 
CRH corticotropin releasing hormone  4 0 
CRHBP corticotropin releasing hormone binding protein 5 1 
CRHR1 corticotropin releasing hormone receptor 1 4 0 
CRHR2 corticotropin releasing hormone receptor 2 4 0 
CRP C-reactive protein, pentraxin-related  4 0 
CSF3 colony stimulating factor 3  1 0 
CTGF connective tissue growth factor  1 0 
CTLA4 cytotoxic T-lymphocyte-associated protein 4  4 1 
CYP19A1 cytochrome P450, family 19, subfamily A, 
polypeptide 1  
4 0 
CYP1A1 cytochrome P450, family 1, subfamily A, 7 2 
12
polypeptide 1  
CYP2C19 cytochrome P450, family 2, subfamily C, 
polypeptide 19  
1 0 
CYP2D6 cytochrome P450, family 2, subfamily D, 
polypeptide 6 
4 0 
CYP2E1 cytochrome P450, family 2, subfamily E, 
polypeptide 1  
2 0 
CYP3A4 cytochrome P450, family 3, subfamily A, 
polypeptide 4  
1 0 
DHCR24 24-dehydrocholesterol reductase  1 0 
DHCR7 7-dehydrocholesterol reductase  1 0 
DHFR dihydrofolate reductase  4 0 
DRD2 dopamine receptor D2  1 0 
EDN2 endothelin 2  4 0 
PROCR protein C receptor, endothelial (EPCR)  1 0 
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic)  5 0 
EPHX2 epoxide hydrolase 2, microsomal (xenobiotic)  4 0 
F13A1 coagulation factor XIII, A1 polypeptide  1 0 
F2 coagulation factor II (thrombin)  9 0 
F5 coagulation factor V  12 4 
F7 coagulation factor VII  7 1 
FAS Fas  4 0 
FASLG Fas ligand 4 0 
FGB fibrinogen beta chain  2 0 
FLT1 fms-related tyrosine kinase 1  1 0 
GNB3 guanine nucleotide binding protein, beta 
polypeptide 3  
1 0 
GSTM1 glutathione S-transferase mu 1  4 2 
GSTP1 glutathione S-transferase pi 1  5 0 
GSTT1 glutathione S-transferase theta 1  5 2 
GSTT2 glutathione S-transferase theta 2 4 0 
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase  
1 1 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1  4 0 
HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7  4 0 
HSPA14 heat shock 70kDa protein 14  4 0 
HSPA1A heat shock 70kDa protein 1A  4 0 
HSPA1B heat shock 70kDa protein 1B 4 0 
HSPA1L heat shock 70kDa protein 1-like  4 1 
HSPA4 heat shock 70kDa protein 4  4 0 
HSPA6 heat shock 70kDa protein 6  4 0 
ICAM1 intercellular adhesion molecule 1 2 1 
ICAM3 intercellular adhesion molecule 3  1 0 
IFNG interferon, gamma  6 2 
IFNGR1 interferon, gamma receptor 1 1 0 
13
IGF1 insulin-like growth factor 1 4 0 
IGFBP3 insulin-like growth factor binding protein 3  4 0 
IL10 interleukin 10  9 2 
IL10RA interleukin 10 receptor, alpha  5 1 
IL10RB interleukin 10 receptor, beta 4 0 
IL11 interleukin 11  1 0 
IL12A interleukin 12A 1 0 
IL13 interleukin 13  5 1 
IL15 interleukin 15  4 1 
IL18 interleukin 18 5 0 
IL1A interleukin 1, alpha  8 1 
IL1B interleukin 1, beta 9 1 
IL1R1 interleukin 1 receptor, type I  5 0 
IL1R2 interleukin 1 receptor, type 2 5 1 
IL1RAP interleukin 1 receptor accessory protein  4 0 
IL1RN interleukin 1 receptor antagonist  10 4 
IL2 interleukin 2 6 1 
IL2RA interleukin 2 receptor, alpha  4 1 
IL2RB interleukin 2 receptor, beta 4 1 
IL4 interleukin 4 8 3 
IL4R interleukin 4 receptor 4 0 
IL5 interleukin 5 4 1 
IL6 interleukin 6 15 5 
IL6R interleukin 6 receptor 7 3 
IL8 interleukin 8 7 0 
IL8RA interleukin 8 receptor alpha 4 0 
ITGA2 integrin, alpha 2 1 0 
ITGB3 integrin, beta 3 1 0 
KL Klotho 4 1 
LCAT lecithin-cholesterol acyltransferase  1 0 
LDLR LDL receptor 1 0 
LIPC lipase, hepatic  1 0 
LNPEP leucyl/cystinyl aminopeptidase  1 0 
LOXL1 lysyl oxidase-like 1  1 0 
LPL lipoprotein lipase  1 0 
LST1 leukocyte specific transcript 1  4 0 
LTA lymphotoxin alpha  5 1 
MASP2 mannan-binding lectin serine peptidase 2  1 0 
MBL2 mannose-binding lectin 2, soluble 10 6 
MMP1 matrix metallopeptidase 1 5 1 
MMP2 matrix metallopeptidase 2 4 1 
MMP3 matrix metallopeptidase 3 5 0 
MMP8 matrix metallopeptidase 8 4 0 
MMP9 matrix metallopeptidase 9 5 2 
MTHFD1 methylenetetrahydrofolate dehydrogenase 4 0 
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MTHFR 5,10-methylenetetrahydrofolate reductase 11 0 
MTR 5-methyltetrahydrofolate-homocysteine 
methyltransferase  
1 0 
MTRR 5-methyltetrahydrofolate-homocysteine 
methyltransferase reductase  
2 1 
NAT1 N-acetyltransferase 1 5 0 
NAT2 N-acetyltransferase 2 6 0 
NFKB1 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 
4 0 
NFKB2 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 
4 0 
NFKBIA nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha  
4 0 
NFKBIB nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, beta 
4 0 
NFKBIE nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, epsilon 
4 0 
NOD2 nucleotide-binding oligomerization domain 
containing 2  
2 1 
NOD2/CAR
D15 
nucleotide-binding oligomerization domain 
containing 2  
4 0 
NOS2A nitric oxide synthase 2, inducible  2 2 
NOS3 nucleotide-binding oligomerization domain 
containing 3 
7 1 
NPPA natriuretic peptide precursor A  1 0 
NQO1 NAD(P)H dehydrogenase, quinone 1  1 0 
NR3C1 glucocorticoid receptor 4 0 
OPRM1 opioid receptor, mu 1  1 1 
OXT oxytocin 1 0 
OXTR oxytocin receptor 1 1 
PAFAH1B1 platelet-activating factor acetylhydrolase, 
isoform Ib, subunit 1  
4 0 
PAFAH1B2 platelet-activating factor acetylhydrolase, 
isoform Ib, subunit 2 
4 0 
PDE4D phosphodiesterase 4D, cAMP-specific  1 0 
PGEA1 chibby homolog 1  4 0 
PGR progesterone receptor 9 1 
PGRMC1 progesterone receptor membrane component 1  4 0 
PGRMC2 progesterone receptor membrane component 2  4 0 
PLA2G4A phospholipase A2, group IVA 4 0 
PLAT plasminogen activator, tissue  6 2 
POMC proopiomelanocortin  4 0 
PON1 paraoxonase 1  7 3 
PON2 paraoxonase 2 6 2 
PPARG peroxisome proliferator-activated receptor 1 1 
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gamma  
PRKCA protein kinase C, alpha 1 1 
PROC protein C 1 0 
PTCRA pre T-cell antigen receptor alpha  4 0 
PTGER2 prostaglandin E receptor 2 5 1 
PTGER3 prostaglandin E receptor 3 4 2 
PTGES prostaglandin E synthase 5 0 
PTGFR prostaglandin F receptor 5 0 
PTGS1 prostaglandin G/H synthase (cyclooxygenase)  4 0 
PTGS2 prostaglandin-endoperoxide synthase 2 4 0 
PTPN22 protein tyrosine phosphatase, non-receptor type 
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4 0 
REN renin  1 0 
RFC1 replication factor C (activator 1) 1 1 0 
RLN1 Relaxin 1 1 0 
RLN2 Relaxin 2 1 0 
RLN3 Relaxin 3 1 0 
SCGB1A1 secretoglobin, family 1A, member 1 
(uteroglobin)  
4 0 
SCNN1A sodium channel, nonvoltage-gated 1 alpha  1 0 
SELE selectin E  2 0 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), 
member 2  
1 0 
SERPINE1 serpin peptidase inhibitor, clade E, member 1  6 1 
SERPINH1 serpin peptidase inhibitor, clade H, member 1 
(collagen binding protein 1)  
6 2 
SFTPC Surfactant protein C 2 0 
SFTPD Surfactant protein D 1 0 
SHMT1 serine hydroxymethyltransferase 1 1 1 
SLC23A1 solute carrier family 23 (nucleobase 
transporters), member 1  
5 0 
SLC23A2 solute carrier family 23, member 2  1 1 
SLC6A4 solute carrier family 6, member 4  4 0 
TCN2 transcobalamin II 4 0 
TFPI tissue factor pathway inhibitor 1 0 
TGFA transforming growth factor, alpha  1 0 
TGFB transforming growth factor, beta 1 0 
TGFB1 transforming growth factor, beta 1 6 0 
THBD thrombomodulin  1 1 
TIMP3 TIMP metallopeptidase inhibitor 3  4 0 
TIMP4 TIMP metallopeptidase inhibitor 4  4 0 
TLR10 toll-like receptor 10  1 1 
TLR2 toll-like receptor 2 6 1 
TLR3 toll-like receptor 3 4 0 
TLR4 toll-like receptor 4  9 2 
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TLR7 toll-like receptor 7 4 0 
TLR8 toll-like receptor 8 4 0 
TLR9 toll-like receptor 9 4 0 
TNF tumor necrosis factor 24 11 
TNFR1 tumor necrosis factor receptor 1 7 4 
TNFR2 tumor necrosis factor receptor 2 3 2 
TNFRSF1A tumor necrosis factor receptor superfamily, 
member 1A  
4 0 
TNFRSF1B tumor necrosis factor receptor superfamily, 
member 1B 
4 0 
TNFRSF6 tumor necrosis factor receptor superfamily, 
member 6b, decoy  
2 1 
TRAF2 TNF receptor-associated factor 2  4 0 
TREM1 triggering receptor expressed on myeloid cells 1  4 1 
TSHR thyroid stimulating hormone receptor  4 0 
UGT1A1 UDP glucuronosyltransferase 1 family, 
polypeptide A1  
4 0 
VEGF vascular endothelial growth factor A  6 1 
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 Chapter 2: Increased risk to siblings of preterm infants suggests genetic factors may 
influence PTB
†
 
 
Abstract 
Adverse pregnancy outcomes, such as PTB, PPROM, placental abruption, and 
preeclampsia, are common and contribute to spontaneous and medically-indicated 
preterm deliveries, with acute and long-term complications for both the mother and 
infant. Etiologies underlying such adverse outcomes are not well understood. As maternal 
and fetal genetic factors may influence these outcomes, we estimated the magnitude of 
familial aggregation as one index of possible heritable contributions. Using the Missouri 
Department of Health’s maternally-linked birth certificate database, we performed a 
retrospective population-based cohort study of births (1989-1997), designating an 
individual born from an affected pregnancy as the proband for each outcome studied. We 
estimated the increased risk to siblings compared to the population risk, using the sibling 
risk ratio, s, and sibling-sibling odds ratio (sib-sib OR), for the adverse pregnancy 
outcomes of PTB, PPROM, placental abruption, and preeclampsia. Risk to siblings of an 
affected individual was elevated above the population prevalence of a given disorder, as 
indicated by S ( S (95% CI): 4.3 (4.0-4.6), 8.2 (6.5-9.9), 4.0 (2.6-5.3), and 4.5 (4.4-4.8), 
for PTB, PPROM, placental abruption, and preeclampsia, respectively). Risk to siblings 
of an affected individual was similarly elevated above that of siblings of unaffected 
individuals, as indicated by the sib-sib OR (sib-sib OR adjusted for known risk factors 
                                                 
†
 This chapter is adapted from: Plunkett J, et al. (2008) Population-based estimate of sibling risk 
for adverse pregnancy outcomes. BMC Genetics, 9:44. 
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 (95% CI): 4.2 (3.9-4.5), 9.6 (7.6-12.2), 3.8 (2.6-5.5), 8.1 (7.5-8.8) for PTB, PPROM, 
placental abruption, and preeclampsia, respectively). These results suggest that the 
adverse pregnancy outcomes of PTB, PPROM, placental abruption, and preeclampsia 
aggregate in families, which may be explained in part by genetics. 
Introduction 
In the United States, 12.7% of births occur preterm (<37 weeks) [66], 
approximately one-fourth of which occur due to PPROM [67]. Preeclampsia, high blood 
pressure and fluid retention in pregnancy, and placental abruption, early detachment of 
the placenta from the uterus, affect approximately 7% [68] and 1% [69] of all 
pregnancies, respectively. While many pregnancies share more than one of these 
complications, together they affect a significant portion of pregnancies and represent the 
most common reasons for early delivery. Moreover, adverse pregnancy outcomes are 
important causes of perinatal morbidity and mortality. For example, placental abruption, 
while uncommon, accounts for 12% of all perinatal deaths [25]. The incidence of PTB 
[66] and placental abruption [25] have increased over recent decades, further motivating 
additional study to understand susceptibility factors which contribute to these outcomes. 
Prediction and prevention of these adverse outcomes is difficult. Etiologies 
underlying PTB, PPROM, placental abruption and preeclampsia are not well understood. 
Genetic studies are one way in which we can attempt to better understand these disorders. 
Such studies may identify genetic markers that can predict one’s risk for a particular 
pregnancy outcome. Genetic studies may also identify novel proteins and/or pathways 
involved in the disorder.  
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 Both maternal and fetal genetic factors may influence adverse pregnancy 
outcomes. Evidence suggests that maternal genetic factors contribute to PTB [70; 71], 
PPROM [71-73], placental abruption [74; 75] and preeclampsia [76-79]. In contrast, fetal 
effects on these outcomes have not been well studied. Several lines of evidence suggest 
that fetal genetic effects may influence adverse pregnancy outcomes. First, fetal genes 
that are paternally imprinted mainly control placental and fetal membrane growth [25]. 
Because the placenta and fetal membranes likely play a role in adverse pregnancy 
outcomes, fetal genes controlling these tissues may also contribute. Additionally, 
heritability studies, which estimate the relative portion of population variation in a trait 
due to genetics, suggest that PTB [22] and preeclampsia [80] are influenced in part by 
fetal genetic factors. Lastly, several studies suggest that paternity affects risk for PTB and 
preeclampsia. For example, several studies indicate that partner changes between 
pregnancies reduce risk of PTB [26; 27] and preeclampsia [80-83]. Changes in paternity 
may reflect association with long interpregnancy intervals rather than paternity effects 
per se; however, for preeclampsia [78; 84], fathers’ family history affects risk for the 
disorder in their partners’ pregnancies. For PTB, father’s family history has been shown 
to have only a weak association with risk. While an early study of a Norway birth registry 
demonstrated a correlation between father and children’s gestational ages [28], a more 
recent and extensive study of this registry suggested fathers contributed little to no risk to 
preterm delivery risk [29]. Also, paternal race has been associated with PTB risk [6; 7]. 
Together, this data suggests that paternal genes expressed in the fetus may contribute to 
these disorders, motivating study of maternal-fetal influences, assessed by defining the 
infant as the proband, in addition to influences that are maternal-specific.  
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 While multiple lines of evidence suggest the importance of genetic contributors in 
adverse pregnancy outcomes, observing clustering of such outcomes in families is 
necessary to assert genetic influences on a disorder. A disorder that does not aggregate in 
families is unlikely to be influenced by inherited factors. Hence, detecting an increased 
risk for a disorder among siblings or other family members of an individual born from a 
pregnancy affected by the same adverse outcome would further support genetic 
influences on these conditions. However, familial aggregation is not sufficient to claim 
genetic influences on a disorder. Since family members share both genes and 
environment, any similarities seen in families may be explained by genetic or shared 
environmental factors (such as in utero environment) or by their interaction.  
Two standard measures of familial aggregation are increase in risk to siblings of 
affected individuals, compared to the population risk for the disorder, the sibling risk 
ratio, s [85], and compared to siblings of unaffected individuals, the sibling-sibling odds 
ratio (sib-sib OR) [86]. These measures have been estimated for a variety of disorders, 
ranging from single locus Mendelian disorders, such as cystic fibrosis [87], to complex 
disorders, including hypertension [88], type 2 diabetes [89], and myopia [90; 91]. These 
familial aggregation measures have been incompletely documented in pregnancy 
outcomes. When considering mother as the affected individual, investigators have 
reported increased risk among first-degree relatives of women affected with PTB [15; 
18], placental abruption [75] and preeclampsia [78; 92]; however, few of these studies 
have scaled the increase in risk among relatives by the population prevalence for a given 
pregnancy outcome (placental abruption [75] , preeclampsia [92] ), as done to calculate 
s. Maternal recurrence risk, similar in calculation to the sib-sib OR, has previously been 
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 reported for these disorders [73; 93-98]. Yet, only one study of PTB and PPROM [73] 
scaled maternal recurrence relative to population prevalence of the disorder and did not 
consider this measure as an indication of familial aggregation. s and sib-sib OR, 
defining the infant of an affected pregnancy as proband, have not been reported for these 
disorders. Estimating s, in which the increased risk for a disorder is scaled by population 
prevalence, is particularly important, as population prevalence can vary by race. While 
there may be a significant increase in risk among siblings or a significant maternal 
recurrence risk, such a risk may reflect high population prevalence, rather than familial 
effects, per se. As a result, calculating s may lead to different conclusions that those 
made by previous reports of maternal recurrence risk. Since individual demographic 
factors, such as socioeconomic status or body mass index, may also contribute to risk, we 
calculate sib-sib OR adjusted for important medical and environmental risk factors to 
assess to what extent genetic effects may account for familial aggregation.  
In order to test whether genetic effects may influence these outcomes, our 
analyses define the infant of an affected pregnancy as the proband. We estimate s and 
sib-sib OR to determine whether each outcome clusters in families.  
Results 
Preterm birth. The population risks for PTB at <35 gestational weeks were 
estimated as 3.6%, 2.8%, and 7.8%, in all races, Whites and Blacks, respectively. Among 
second-born siblings in the sibling subcohort whose older sibling was affected, rates of 
PTB for all races, Whites and Blacks, respectively, were used to estimate the sibling risk 
(see Table 2.1). S and its 95% CI were 4.3 (4.0-4.6), 4.4 (4.0-4.7), and 2.8 (2.6-3.1) for 
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 all races, Whites, and Blacks, respectively, indicating a significant increase in risk to 
siblings of PTB patients compared to the population. 
Individuals whose older sibling was affected by PTB were also at significantly 
higher risk compared to individuals whose older sibling was unaffected (see Table 2.1). 
This increase in risk persisted after adjusting for known risk factors. Adjusted OR with 
95% CI were 4.2 (3.9-4.5), 5.1 (4.6-5.7), and 3.3 (2.9-3.7) for all races, Whites and 
Blacks, respectively.  
PPROM. The population risks for PPROM were estimated as 0.8%, 0.6% and 
1.9%, in all races, Whites and Blacks, respectively. Among second siblings in the 
matched sibling sub-cohort whose older sibling was affected, rates of PPROM were used 
to estimate sibling risk (see Table 2.2). S and its 95% confidence interval were 8.19 
(6.50-9.88), 6.75 (4.59-8.91), and 6.40 (4.66-8.14) for all races, Whites, and Blacks, 
respectively, indicating a significant increase in risk to siblings of PPROM patients 
compared to the population.  
Individuals whose older sibling was affected by PPROM were also at 
significantly higher risk compared to individuals whose older sibling was unaffected (see 
Table 2.2). This increase in risk persisted after adjusting for known risk factors. Adjusted 
OR with 95% CI were 9.6 (7.6-12.2), 8.5 (6.0-12.1), and 8.9 (6.4-12.5) for all races, 
Whites and Blacks, respectively.  
Placental Abruption. Population rates of placental abruption were estimated as 
0.8%, 0.7%, 1.0%, in all races, Whites and Blacks respectively. Among second siblings 
in the matched sibling sub-cohort whose older sibling was affected, rates of placental 
abruption were used to estimate risk to siblings (see Table 2.3). S and its 95% 
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 confidence interval were 3.95 (2.63-5.27) and 4.93 (3.18-6.68), for all races and Whites, 
respectively, indicating a significant increase in risk to siblings of placental abruption 
patients compared to the population. 
We found that individuals whose older sibling was affected by placental abruption 
were also at significantly higher risk compared to individuals whose older sibling was 
unaffected (see Table 2.3). This increase in risk persisted after adjusting for known risk 
factors. Adjusted OR with 95% CI: 3.8 (2.6-5.5) and 5.0 (3.4-7.4) for all races and 
Whites, respectively. 
Blacks did not show a significant increase in risk to siblings of placental 
abruption births either compared to the population ( S= 1.64 (0.04-3.24)) or compared to 
siblings of births unaffected by this disorder (unadjusted OR: 1.4 (0.5-3.7), adjusted OR: 
1.2 (0.4-3.9)).  
Preeclampsia. Population rates of preeclampsia were estimated as 3.2%, 3.1%, 
and 4.1%, in all races, Whites and Blacks, respectively. Among second siblings in the 
matched sibling sub-cohort whose older sibling was affected, rates of preeclampsia were 
used to calculate sibling risk (see Table 2.4). S and its 95% confidence interval were 
4.51 (4.24-4.78), 4.52 (4.21-4.83), and 4.11 (3.59-4.63) for all races, Whites, and Blacks, 
respectively. 
We found that individuals whose older sibling was affected by preeclampsia were 
also at significantly higher risk compared to individuals whose older sibling was 
unaffected (see Table 2.4). This increase in risk persisted after adjusting for known risk 
factors. Adjusted OR with 95% CI were 8.1 (7.5-8.8), 9.0 (8.2-9.8), and 5.8 (4.9-7.0) for 
all races, Whites and Blacks, respectively.  
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 Discussion 
We hypothesized that siblings of individuals who were products of pregnancies 
affected by one of several adverse outcomes, PTB, PPROM, placental abruption and pre-
eclampsia, would be at increased risk for the same outcome. s and sib-sib OR values 
significantly greater than one indicate that risk to siblings of adverse pregnancy outcome 
births is elevated compared to the population rate and to the rate in siblings of unaffected 
individuals, respectively. None of the 95% CI for s or sib-sib OR values overlap with 
one, with the exception of placental abruption in Blacks. The lack of evidence for familial 
aggregation of placental abruption in Blacks may be explained by the rarity of the event 
and the relatively small racial subgroup (see Table 2.3). These data suggest that genetic 
and/or environmental risk factors shared among siblings affect these disorders.  
Estimates of sib-sib OR are consistent with previous studies of maternal 
recurrence risk in the Missouri birth certificate database [93; 94], and of maternal 
recurrence risk scaled to the population prevalence for PTB [73]. Our estimate of s is 
noticeably smaller than the maternal recurrence risk, scaled by population prevalence of 
PPROM estimated in [73] (OR (95% CI): 20.6 (4.7, 90.2)). This difference likely reflects 
the larger and population-based cohort used in our study, in contrast to [73] in which 
relatively small groups of PPROM (n=114) and normal term (n=208) deliveries were 
selected from a hospital population. 
The utility of these measures lies primarily in establishing familial aggregation of 
a disorder, a prerequisite to claiming genetic influences on any trait. Yet, s values may 
also be used to make tentative assessments of future genetic studies. The magnitude of s 
values may reflect the mode of genetic etiology, influencing future studies’ design. For 
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 example, for complex disorders, to which multiple genetic and environmental factors 
likely contribute, reported s values range from 1.3-75, with peaks at 3-4 and 10-15 [88]; 
in contrast, monogenic Mendelian disorders show s values an order of magnitude higher 
or more (e.g. cystic fibrosis s ~500 [87]). Thus, moderate values for s, such as those 
reported for the adverse pregnancy outcomes studied (see Tables 2.1-2.4), are consistent 
with complex genetic and environmental etiologies. Among complex disorders, s has 
been used to estimate the ability of a study to detect specific genes [99]. However, large 
values of s do not necessarily predict linkage [88; 100] or association [101] studies’ 
success. Additionally, measures that reflect the strength of a genetic effect detected either 
by linkage, s calculated with respect to a specific locus, or by association, genotype 
relative risk, γ, which measures the ratio of disease risks between individuals with and 
those without the susceptibility genotypes, have only an indirect correlation with s 
[101]. Moderate s values may correspond with high γ values (e.g. rheumatoid arthritis 
[101]) and vice versa. While limitations in interpreting s values exist, disorders with 
similar s values to the adverse pregnancy outcomes reported here have had specific 
genes mapped (e.g. hypertension, obesity [88]), suggesting that identification of specific 
genes influencing these conditions may be possible.  
While the increased risk to siblings may be explained in part by shared genetics, 
some evidence suggests that multiple interacting environment factors can account for 
familial clustering [102]. Hence, the clustering of multiple non-genetic risk factors in 
families may account for these results. In order to distinguish genetic from other familial 
risk factors, we calculated sib-sib OR unadjusted and adjusted for important known 
environmental risk factors. Overall, the elevated risk to siblings persists after adjustment 
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 for such factors. While there may be important non-genetic factors affecting each 
outcome for which we have not accounted, we believe these results suggest that genetic 
influences may contribute to each of the adverse pregnancy outcomes studied.  
Interestingly, s and sib-sib OR estimates in Blacks are generally smaller than 
those for Whites. For PROM and preeclampsia, the 95% CI for s and sib-sib OR 
estimates for the two racial groups overlap; however, these CI do not overlap for PTB or 
placental abruption. Hence, it is difficult to determine to what extent family clustering of 
these outcomes may differ among races. Differences in the magnitude of s and sib-sib 
OR estimates between Blacks and Whites may be explained in part by the higher 
population prevalence for Blacks compared to Whites for each outcome studied (non-
overlapping 95% CI, see Tables 2.1-2.4), which may reflect higher overall rates of 
genetic and/or environmental risk factors in this population.  
The Missouri database provides many of this study’s strengths. The large number 
of first recorded siblings in the population cohort (n=267,472) and matched sibpairs in 
the sibling cohort (n=163,826) provides a large sample size from which to estimate s 
and sib-sib OR. Additionally, because this database represents a population cohort of 
births, rather than births selected based on any particular pregnancy outcome, biases due 
to ascertainment and overreporting, which can inflate s values [103], should be minimal.  
However, using a birth certificate database like this one also presents several 
limitations. First, complications of labor and delivery and maternal and infant medical 
conditions recorded in such databases may be underreported [104]; as a result, population 
and/or sibling risk for a particular disorder may be underestimated, potentially biasing 
our results. For example, the relative rarity of placental abruption in the population makes 
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 concordant sibships, particularly in Blacks, rare, thereby reducing sample sizes for risk 
estimates for this disorder. Additionally, gestational age estimates contained in birth 
certificate databases are based primarily on the date of the last menstrual period, which 
may be recalled inaccurately or misclassified due to postconceptional bleeding [104], 
potentially influencing estimates of PTB and PPROM prevalence in this dataset. We also 
acknowledge that each of the categories of PTB that we analyzed may in themselves be 
rather heterogeneous. For example, initiation of spontaneous labor may result in PTB in 
each of the categories, though for some etiologies, particularly preeclampsia, iatrogenic 
delivery could contribute significantly. Our utilization of a more rigorous definition of 
PTB at less than 35 weeks should minimize the contribution of iatrogenic delivery. A 
final important limitation to this database is the limited amount of information on race. 
Maternal race is self-reported and possibly subject to population stratification and/or 
admixture. Additionally, information on paternal race is incomplete, further affecting the 
accuracy of infants’ reported race. 
The Missouri database also does not document relationships between mothers; as 
a result, similar calculations cannot be made to estimate familial clustering when the 
mother of an affected pregnancy is considered the proband. Moreover, the database 
contains little information on fathers, making it impossible to distinguish full from half 
siblings in most sibships. Because we cannot distinguish siblings that share both maternal 
and paternal factors from those that share maternal factors only, we cannot assess to what 
extent the increased risk can be attributed to factors unique to the fetus, rather than those 
shared with its mother. Due to these limitations, we cannot examine the relative 
importance of maternal versus fetal genetic effects, studied by Wilcox et al. [29] and 
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 Cnattingius et al. [80], for PTB and preeclampsia, respectively. Cnattingius et al. [80] 
reports 20% of variation in preeclampsia risk is due to fetal genetic effects and the 
combined effect of fetal genetic factors and couple effects are as important as maternal 
genetic effects. In contrast, Wilcox and colleagues [29] report only a weak association 
between father’s family history and risk for PTB (RR (95% CI): 1.12 (1.01-1.25)), which 
became nonsignificant at earlier gestational ages (RR (95% CI): 1.06 (0.77-1.44). From 
this trend, the authors conclude that fetal genes may contribute to normal labor, but, not 
preterm delivery [29]; however, Wilcox and colleagues [29] have relatively few early 
preterm offspring of early preterm mothers (n=91) and fathers (n=39) from which risk 
was estimated, and do not stratify based upon race/ethnicity. Similarly, a recent study 
[21] suggested that paternal genetics contributed little to gestational age, but could not 
refute the possible role of maternally-inherited genes expressed in the fetus. Hence, while 
paternally-inherited genes may contribute little to PTB or other disorders, maternally-
inherited genes expressed in the fetus may still be important. Because of our study’s 
limitations, we may be detecting effects due to shared uterine environment, shaped in part 
by maternal genes, rather than maternally-inherited genes in siblings. Hence, fetal genetic 
effects may make contributions of lesser magnitude than maternal genetic factors, with 
fetal genetic factors having a more prominent role in certain etiologies of PTB. 
We have observed familial aggregation of PTB, PPROM, placental abruption and 
preeclampsia. Overall, siblings are at increased risk for each outcome, even after 
adjusting for important known environmental risk factors. While the influence of shared 
unmeasured environmental risk factors on sibling risk cannot, and should not, be 
discounted, we hypothesize that maternal and/or fetal genetic influences account for some 
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 of the increased risk to siblings observed. Moreover, though it is difficult to determine to 
what extent fetal and maternal effects overlap in these analyses, we postulate that fetal 
genetic factors may contribute to these disorders and suggest that they are studied further.  
Methods 
Study design. A protocol was approved by the Missouri Department of Health 
and Senior Services and by Washington University School of Medicine to analyze the 
state’s maternally linked birth-death certificate database. We analyzed this database to 
assess the recurrence risk for a discrete group of adverse pregnancy outcomes, including 
PTB, PPROM, placental abruption, and pre-eclampsia, in maternally-linked siblings. 
Births to the same mother were linked by a unique identifier called a sibship number, 
described elsewhere [105]. Full siblings and half-siblings resulting from pregnancies in 
the same mother were not distinguished. All protected health information with personal 
identifiers was removed before distributing the data for analysis. 
This analysis was restricted to births that occurred between 1989 and 1997, since 
births that occurred before 1989 lacked complete medical and social histories. Fetal 
deaths occurring at <20 weeks gestation, multiple gestation pregnancies and individuals 
with no maternally-linked siblings recorded in the database were excluded from this 
analysis. After excluding such cases, the remaining cohort consisted of 473,881 births, of 
which 383,812 (81.2%) were White and 81,889 (17.3%) were Black. 267,472 births 
(220,728 (82.5%) White and 42,899 (16.0%) Black) were the first maternally-linked 
sibling in the database and used to estimate the population prevalence for each outcome. 
A second cohort of matched siblings was constructed from this dataset to analyze 
sibling risk for each outcome. The two oldest siblings born to the same mother during the 
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 study period were included. The dataset was not restricted to parity 0 and parity 1 
women, in order to be as unbiased as possible in estimating risk for siblings and 
providing the best index of population prevalence. Additional siblings born to the same 
mother were excluded to simplify the statistical model. This cohort comprised of 327,652 
matched siblings, of which 265,947 (81.2%) were White and 55,555 (17.0%) were Black. 
Second-born siblings whose older sibling was affected by a particular outcome were used 
to estimate sibling risk for s and sib-sib OR. 
Definitions. PTB is defined by the World Health Organization as delivery <37 
weeks [1]. To avoid inclusion of borderline gestational ages which may introduce 
misclassification bias, we defined PTB as delivery <35 weeks in this study. Information 
from the last menstrual period and clinical data were used to calculate the best estimate of 
gestational age. PPROM was defined as births delivered <35 weeks complicated by 
premature rupture of membranes. For PPROM, births complicated by pre-eclampsia, 
insulin-dependent and other diabetes, or eclampsia were excluded from analysis due to 
the potential for these births being delivered for medical reasons. First-born sibling and 
second-born sibling refer to the two oldest siblings recorded in database.  
Statistical analysis
prevalence Population
sibling)  affected|P(affected
s
S was calculated as the frequency of an outcome in the individuals whose older 
sibling was affected with the disorder in the sibling cohort divided by the frequency of 
the outcome in first siblings in the larger cohort. 95% confidence intervals (CI) for 
sibling risk, population risk and sibling risk ratio were calculated by standard procedures 
for a binomial variable.  
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 sibling)  unaffected|P(affected
sibling)  affected|P(affected
OR  sibSib  
Sib-sib OR was calculated as the odds of a child being affected with a particular 
adverse outcome, given that their older sibling was affected, divided by the odds of a 
child being affected with a particular adverse outcome, given that their older sibling was 
unaffected. Sib-sib OR were adjusted for known medical and environmental risk factors 
for the outcome to most conservatively estimate residual familial effects on risk. For 
preterm-birth and PPROM, OR were adjusted for: mother’s age <20 years old, mother 
<12 years of education, recipient of state-funded assistance (an index of low 
socioeconomic status), no prenatal care, mother’s body mass index (BMI) <20 kg/m2, and 
cigarette smoking during pregnancy. In addition to these risk factors, preeclampsia ORs 
were corrected for: mother’s age >35years old, insulin-dependent diabetes mellitus, 
chronic hypertension. ORs for placental abruption were corrected for 
hydraminos/oligohydraminos in addition to the risk factors listed above. 
Frequencies for S and logistic regression analyses for the sib-sib OR were 
performed using Stata 9 [106]. Each calculation was made for PTB, PPROM, placental 
abruption, and preeclampsia in all races (including individuals whose race was neither 
Black nor White), as well as stratified by Black or White race. S and sib-sib ORs 
calculated by race compare siblings of affected individuals designated as Black or White 
to the siblings of unaffected individuals of the same race or the population prevalence for 
that race.  
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 Chapter 3: Patterns of inheritance suggest familial PTB is complex genetic disorder
‡
 
 
Abstract 
While multiple lines of evidence suggest the importance of genetic contributors to 
risk of PTB, the nature of the genetic component has not been identified. We perform 
segregation analyses to identify the best fitting genetic model for gestational age, a 
quantitative proxy for PTB. Because either mother or infant can be considered the 
proband from a preterm delivery and there is evidence to suggest that genetic factors in 
either one or both may influence the trait, we performed segregation analysis for 
gestational age either attributed to the infant (infant’s gestational age), or the mother (by 
averaging the gestational ages at which her children were delivered), using 96 multiplex 
preterm families. 
These data lend further support to a genetic component contributing to birth 
timing since sporadic (i.e. no familial resemblance) and nontransmission (i.e. 
environmental factors alone contribute to gestational age) models are strongly rejected. 
Analyses of gestational age attributed to the infant support a model in which mother’s 
genome and/or maternally-inherited genes acting in the fetus are largely responsible for 
birth timing, with a smaller contribution from the paternally-inherited alleles in the fetal 
genome. Our findings suggest that genetic influences on birth timing are important and 
likely complex. 
 
 
                                                 
‡
 This chapter is adapted from: Plunkett J, et al. (2009) Mother’s genome or maternally-inherited 
genes acting in the fetus influence gestational age in familial PTB. Hum Hered 68:209-219. 
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 Introduction  
While multiple lines of evidence suggest genetic contributors are important in 
PTB, a specific mode of inheritance has not been identified. No prominent simple 
Mendelian pattern of inheritance has been observed in multiplex pedigrees identified to 
date. Modeling procedures used by twin studies suggest that additive genetic factors and 
environmental risk factors that are not shared among siblings both influence PTB [19-
21]. Moderate values of sibling risk ratio ( S), a measure of risk to siblings of affected 
individuals compared to the population risk for a disorder, estimated for PTB ( S (95% 
CI): 4.3 (4.0-4.6)) [107] are also consistent with complex genetic and environmental 
etiologies [88]. Moreover, association studies have reported gene-gene [33; 34] and gene-
environment [35; 108; 109] interactions with PTB. Together, these studies imply that the 
etiology of PTB likely involves genetic as well as environmental factors in complex 
interactions. However, there has not been a systematic study of possible genetic models 
for PTB to date. 
In this study, we performed segregation analyses to identify the best fitting 
genetic model for gestational age, a quantitative proxy for PTB. Because either mother or 
infant can be considered the proband from a preterm delivery, and there is evidence to 
suggest that genetic factors in either one or both may influence the trait, we performed 
segregation analysis for gestational age as a quantitative trait either attributed to the 
infant, infant’s gestational age, or to the mother, by averaging the gestational ages at 
which her children were delivered, using 96 multiplex preterm families. We also tested 
parent of origin models for infant’s gestational age to examine whether mother’s 
genotype is the sole determinant of variation in this trait. Additionally, as pregnancies in 
38
 which either the mother [10; 13] or father [6; 7] is Black are at increased risk for preterm 
delivery, we performed segregation analysis for each phenotype in the total sample, as 
well as stratified by Black and White race, to test for heterogeneity between these two 
groups.  
Results 
Modeling of gestational age attributed to the infant. We first analyzed 
gestational age of the infant. The number of subjects and descriptive statistics for this 
phenotype are shown in Table 3.1. Table 3.2 presents the likelihood ratio tests (LRTs) 
and Akaike’s Information Criterion (AIC) values for segregation analysis of infant’s 
gestational age for 17 models of inheritance. The parameter estimates for segregation 
analysis of infant’s gestational age are listed in Table 3.1. The hypotheses of no familial 
resemblance (model 2), no major gene effect (model 3), and no multifactorial effect 
(model 4) are rejected, suggesting the presence of both a major gene and a multifactorial 
effect. Additionally, the equal τ's hypotheses (models 10, 12 and 14) are rejected for the 
mixed, recessive mixed and dominant mixed models, respectively. In the free τ's models, 
the estimated τAa differed from 0.5, expected under the Mendelian model, and fit the data 
better than their respective general models (models 1, 7 and 8) for all groups. Together, 
this evidence supports a genetic component for PTB transmitted from parents to offspring 
and suggests that the transmitted effect is complex. Similar models were tested for 
general parent of origin effects, as well as maternal-specific and paternal-specific effects 
under Mendelian transmission (models 15-17). The parent of origin model (model 15) 
best fit the data as judged by AIC values and was chosen as the most parsimonious model 
(Table 3.3). This model suggests that, when attributing gestational age to the infant of a 
39
 delivery, genetic factors influence this trait and the parent from whom such factors are 
inherited influences the overall trait value. 
Modeling of gestational age attributed to the mother. We also analyzed 
gestational age attributed to the mother, by averaging the gestational ages at which her 
children were delivered (see Table 3.1). Table 3.2 presents the likelihood ratio tests and 
AIC values for segregation analysis on mother’s average gestational age of children for 
14 models of inheritance. The parameter estimates for the combined dataset are listed in 
Table 3.4. The hypotheses of no familial resemblance (model 2), no major gene effect 
(model 3), and no multifactorial effect (model 4) are rejected, suggesting the presence of 
both a major gene and a multifactorial effect. The equal τ's (models 10, 12 and 14) are 
rejected. None of the free τ's models (models 9, 11 and 13) converged initially. In order to 
estimate these models, τAA and τaa were fixed to 1 and 0, respectively. Only τAa was 
estimated and, in each case, differed from 0.5, expected under the Mendelian model. 
Additionally, the free τ's models fit the data better than their respective general models 
(models 1, 7 and 8), perhaps suggesting that the major effect observed is more complex 
than the single biallelic locus modeled here. Together, this evidence supports a genetic 
component for PTB transmitted from parents to offspring and suggests that the 
transmitted effect is complex. The mixed free ’s model (model 9) best fit the data as 
judged by the AIC values and was chosen as the most parsimonious model (Table 3.5). 
This model suggests that a multifactorial genetic model most likely best accounts for 
variation in gestational age, when the trait is attributed to the mother of a delivery. 
Heterogeneity between Blacks and Whites. Since pregnancies in which either 
the mother [10; 13] or father [6; 7] is Black are at increased risk for preterm delivery, we 
40
 tested for evidence of genetic heterogeneity between these two groups. Segregation 
analyses of infant’s gestational age and mother’s average gestational age over all her 
children also were performed in Black and White subgroups. Table 3.1 documents the 
number of subjects and descriptive statistics for both phenotypes by race. The segregation 
analyses of infant’s gestational age supported similar conclusions in the combined sample 
and Black and White subgroups. However, several results differed in the segregation 
analysis of mother’s average gestational age of children when the sample was stratified 
by Black and White race, compared to the combined sample. In the race-stratified 
samples, final estimates of the free τ's models had higher -2ln likelihoods than did similar 
models with fewer parameters, indicating that the maximum likelihood was not reached. 
As a result, the equal τ's hypotheses (models 10, 12 and 14) and the free τ's hypotheses 
(models 9, 11 and 13) were not rejected for the mixed, recessive mixed and dominant 
mixed models, respectively, in Black and White subgroup analysis. The best fitting 
model according to AIC values was the mixed equal τ's model and was selected as the 
most parsimonious model in both race subgroups (data not shown).  
To test formally for heterogeneity between Blacks and Whites, we used the 
heterogeneity 
2
 test [110; 111] in which the -2lnL value under a given model for the 
combined data is subtracted from the summed -2lnL values from stratified analyses. For 
infant’s gestational age, evidence for genetic heterogeneity among races was observed 
when comparing values under the multifactorial model (
2 
= 698.07 Black + 2010.02 
White) -2690.72 combined =17.37, 3 df, p=0.0006). Of note, parameter estimates for 
Blacks and Whites differed, particularly estimates of p, H and AA which were generally 
higher in Blacks than Whites. For the multifactorial model, H was estimated as 0.46 
41
 (95% CI: 0.27, 0.65) for Blacks and 0.23 (95% CI: 0.13, 0.33) for Whites. While these 
point estimates are quite different, the 95% CI overlap, indicating that this difference may 
not be statistically significant. For mother’s average gestational age of children, evidence 
for genetic heterogeneity among races was observed when comparing values under the 
multifactorial model (
2 
= (54.92 Black +213.58 White)-216.37 combined =52.13, 3 df, 
p=2.81x10
-11
). Of note, parameter estimates for Blacks and Whites differed, particularly 
estimates of H, which are generally higher in Blacks than Whites. For the mixed free τ's 
model, H was estimated as 0.70 (95% CI: 0-1) for Blacks and 0.23 (95% CI: 0-0.57) for 
Whites. As the 95% confidence intervals overlap, this difference is not significant in the 
sample size analyzed here. 
Discussion 
PTB likely has a complex etiology involving both genetic and environmental risk 
factors, based on evidence from previous studies. This study is the first to explicitly test 
different modes of inheritance for birth timing, by assessing gestational age as a 
phenotype of either mother or infant. These data lend further support to a genetic 
component contributing to birth timing since sporadic (i.e. no familial resemblance) and 
nontransmission models, in which gestational age is attributed to environmental factors 
alone, are strongly rejected (Tables 3.2 and 3.4). Our findings suggest that genetic 
influences on birth timing are important and likely complex.  
For infant’s gestational age, the parent of origin model (model 15) best fit the data 
according to the AIC values and was chosen as the most parsimonious model (Table 3.2). 
Based on the mean estimates for AA, Aa, aA and aa under this model (Table 3.3), it 
appears that this parent of origin effect is largely maternal. Heterozygotes who inherit the 
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 A allele from their mother (Aa) have a mean closer to, but not equal to, AA. Under a 
strict maternal model, AA and Aa would be equivalent, since mother’s A allele would be 
expected to be the sole determinant of phenotype. In contrast, heterozygotes who 
inherited the A allele from their father (aA) have a mean that is approximately equivalent 
to that of aa, suggesting that father’s A allele has little effect on phenotype. A model in 
which the maternally-inherited allele was the sole determinant of the phenotype (model 
16) did not fit the data better than the parent of origin model in which the entire genotype 
was considered. Importantly, father’s genes also affect phenotype in this model, aligning 
with previous work showing paternity [26; 27] as well as paternal race [6; 7] influence 
PTB risk. Hence, both maternal and paternal alleles seem to contribute to infant’s 
gestational age, with maternally-inherited alleles having a stronger effect on phenotype 
than those inherited from the father. This finding may support previous studies that have 
observed stronger effects of mother’s race [6; 7] and family history on risk for PTB [29] 
than those of the father. 
These data suggest that maternally-inherited genes acting in the fetus and/or 
maternal genes acting in the mother are largely responsible for birth timing; however, 
these two possibilities are not easily distinguished. Maternal genetic effects can create the 
same pattern of phenotypic variation as genomic imprinting [112]. These two classes of 
effects can be distinguished by comparing the offspring of heterozygous mothers [112]; 
however, such comparisons are not possible in our dataset in which individuals were 
assigned probabilities for each possible genotypic state, rather than having known 
genotypes measured empirically. Previous studies in cattle [113; 114] have observed 
maternal genetic effects on gestational age, but did not consider parent of origin effects. 
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 Consequently, further study is needed to determine whether maternal effects or 
imprinting account for our observations. In either case, considering the mother of a 
preterm delivery as proband may be most useful in identifying genetic contributions to 
PTB.  
Segregation analysis of mother’s average gestational age of children also 
supported a complex genetic model. The mixed free τ's model (model 9) best fit the data 
according to the AIC values and was chosen as the most parsimonious model (Table 3.4). 
This model, in combination with results from LRTs, suggests that genetic influences on 
birth timing are important and likely complex. Importantly, fewer individuals are 
informative when mother is considered the proband in a preterm delivery (Figure 3.1), 
and the smaller sample size affects the power of the analysis. As a result, the parameter 
and likelihood estimates made when considering mother as proband are more affected by 
sampling variance; however, conclusions made by comparing across models should be 
less affected by sample size.  
Overall, mother-based and infant-based analyses both support the importance of 
genetic factors, perhaps primarily acting in the mother or maternally-inherited alleles 
acting in the fetus, in birth timing. The genetic component influencing PTB likely 
involves many genes in interaction with environmental and other genetic factors. These 
results are consistent with previous studies suggesting that genes and environments [19-
21], as well as gene-gene [33; 34] and gene-environment [35; 108; 109] interactions 
influence PTB. Estimates from the multifactorial model (model 3, Tables 3.3 and 3.5) 
indicate 30-40% of variation in gestational age, attributed to either mother or infant, can 
be explained by genetics, consistent with estimates from previous twin studies [19; 21]. 
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 As twins may not be representative of the population as a whole, our heritability 
estimates corroborate the general importance of genetics in birth timing. Heritability 
estimates were generally higher in mother-based analyses (0.44 (95% CI: 0.11, 0.77)) 
than in infant-based analysis (0.33 (95% CI: 0.24, 0.42)), but not significantly different 
(Tables 3.3, 3.5). While many genes may be contributing to the observed genetic 
influence on birth timing, the moderate heritability observed suggests that the cumulative 
effect of these genes accounts for an important amount of variation in gestational age.  
Although alternative methods for segregation analysis exist, we considered the 
Pedigree Analysis Package (PAP) to be the best method for our primary goal of 
identifying the best-fitting genetic model for birth timing. Using PAP, we were able 
compare models directly and identify the most parsimonious model. In contrast, Markov 
Chain Monte Carlo (MCMC) methods, such as those used by the Loki [115] and Morgan 
[116] packages, generate a series of posterior probabilities for various models, but no one 
model is identified as superior. Moreover, MCMC methods model several Mendelian loci 
simultaneously but do not include a polygenic component, which we wanted to include in 
the models we examined. Furthermore, one cannot correct for ascertainment within 
MCMC analysis, in contrast to PAP. One of the disadvantages of using PAP exclusively 
was that we were not able to estimate the approximate number of loci contributing to 
birth timing, as could be done with MCMC methods. Additionally, MCMC methods may 
be better at handling large, complex pedigrees than PAP [117]; however, since our 
families were relatively small and simple (e.g. containing no inbreeding), we did not 
consider this a limitation. 
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 We have likely enriched for genetic and/or common environmental effects by 
using 96 multiplex families, all of whom were recruited based on having two or more 
first degree relatives delivered preterm. These multiplex families provided a large sample 
size from which genetic effects could be examined. However, the ascertainment scheme 
also introduces bias, as the families were not collected randomly and may overestimate 
the importance of certain genetic models. To minimize errors due to such bias, all 
analyses were corrected for ascertainment by conditioning on the initial proband, either 
the mother or the offspring depending which phenotype was considered, that led to the 
ascertainment of the family, assuming single ascertainment. However, if our assumption 
of single ascertainment is incorrect, conditioning on probands in this manner may create 
bias in estimating model parameters [118], leading to inaccurate conclusions about the 
best-fitting model for familial PTB. Because we believe our ascertainment scheme is 
consistent with single ascertainment, these results appear to be most appropriate for 
modeling genetic effects in familial PTB. Yet, it is possible that our conclusions drawn 
from familial cases of PTB may not generalize to all instances of this disorder. Familial 
cases of PTB may have a different genetic contribution than isolated cases, perhaps 
having different etiologies than isolated cases. 
This study is also limited by the phenotypes studied. Information on gestational 
age was collected by self-report data from questionnaires for many individuals used in 
this analysis. While it was possible to verify gestational ages from medical records in 
some cases, including all births delivered at the participating institutions, many 
gestational ages could not be verified and may be subject to reporting errors. 
Additionally, many individuals for whom we could not verify precise gestational ages 
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 were reported as “full term” and assigned gestational age of 40 weeks. While this is the 
most likely gestational age for infants to be born [12], we may lose some variability in 
the overall distribution of gestational age by doing so. As modeling of trait variance is 
essential to segregation analysis, this approach also may have affected our results. 
Our findings suggest that genetic influences on birth timing are important. 
Modeling for both mother and infant phenotypes indicate that a genetic component 
influences gestational age and is complex in nature. In analyses using either mother or 
infant as proband, monogenic Mendelian models were strongly rejected, suggesting that a 
single gene model cannot fully explain birth timing in these families. A number of genes 
probably contribute to the genetic influence on birth timing and PTB described. Analyses 
of gestational age attributed to the infant support a model in which mother’s genome 
and/or maternally-inherited genes acting in the fetus are largely responsible for birth 
timing, with a smaller contribution from the paternally-inherited alleles in the fetal 
genome. Hence, considering the mother of a preterm delivery as proband may be more 
useful in identifying specific genetic contributions to PTB. Interestingly, results from the 
heterogeneity 
2
 test comparing race-stratified analyses suggest that genetic influences on 
birth timing may differ between Blacks and Whites. Hence, in future association studies, 
race-stratified analyses or population stratification corrections may improve our ability to 
identify specific genes associated with PTB. Overall, as multiple genes in the mother’s 
genome may explain the bulk of genetic influences on birth timing, future studies to 
identify specific genes influencing PTB perhaps will be most fruitful by using large scale 
studies of mothers’ genomes.  
Material and Methods 
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 Proband mother-infant pair was initially identified through premature birth of a 
live singleton fetus before 37 weeks of gestation [1] by review of delivery logs at 
university medical center hospitals at Washington University and University of Helsinki 
or by self-identification through the study’s website from 2003 to October 2007. To avoid 
misclassification bias at borderline gestational ages, we defined PTB as <35 weeks in the 
US cohort and <36 weeks in the Finland cohort. Our gestational age criteria was less 
stringent in the Finland cohort due to the high number of early ultrasounds performed, 
leading to more accurate gestational ages in this cohort. To include only families with 
spontaneous onset of preterm singleton birth, the following mother-infant pairs were 
further excluded: elective deliveries without spontaneous onset of labor and deliveries in 
which either maternal (e.g. systemic infection) or fetal (e.g. malformation) disease with 
known predisposition to premature birth was indicated. Families were extended through 
affected individuals on both maternal and paternal sides until no additional first degree 
relatives were identified as either mother of infant of a preterm delivery. Families were 
recruited into the study only if two or more members were mothers and/or infants of 
preterm deliveries. 55 families were recruited from the US, of which 31 were Black and 
24 were White. 41 White families were recruited from Finland. In the US cohort, families 
ranged from 9 to 36 individuals with phenotypic information with a median family size of 
18 individuals. In the Finland cohort, families ranged from 8 to 73 individuals with 
phenotypic information with a median family size of 16 individuals. Informed consent 
was obtained from participants and the study was approved by the institutional review 
board of Washington University School of Medicine and the ethics committee of Helsinki 
University Central Hospital.  
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 From the US cohort, an individual’s gestational age was calculated based on his 
or her mother’s self report of expected due dates and actual delivery dates for a 
pregnancy or of how many weeks early that family member was born. For all individuals 
born at the Washington University School of Medicine, gestational ages were verified 
from medical records. From the Finland cohort, an individual’s gestational age was 
obtained from medical records. Individuals for whom pedigree information indicated that 
they were born <35 or <36 weeks without a specific gestational age designated were 
assigned a gestational age of 34 or 35 weeks, respectively. Similarly, those individuals 
indicated as “term” were designated 40 weeks. Infant’s gestational age was treated as a 
quantitative trait, which was standardized to a normal distribution ( =0, =1) prior to any 
analysis. A total of 1378 individuals had non-missing phenotypes, with a median of 13 
individuals per family (range 3-80). The number of sibpairs with phenotypic information 
for this phenotype was 309, with a median of 3 sibpairs per family (range 1-7). The 
median number of generations with phenotypic information was 3 (range 1-5).  
For both cohorts, a variable representing the average gestational age of all 
children born to a given mother was constructed. For mothers who had one or more 
children born before 37 weeks, this variable was calculated as the mean of the gestational 
ages for all children born to that woman. Mothers who gave birth to all of their children 
at term (>37 weeks) were assigned a value of 40 weeks. Mothers for whom one or more 
children had missing gestational ages were coded as missing. Additionally, all males and 
females who had not yet given birth were coded as missing. This phenotype was treated 
as a quantitative trait, which was standardized to a normal distribution ( =0, =1) prior 
to any analysis. Univariate statistics and standardizations for each phenotype were 
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 performed with SAS language v. 9.1.3 for Linux OS (SAS Institute, Cary, NC). A total of 
404 individuals had non-missing phenotypes, with a median of 4 individuals per family 
(range 1-17). The number of sibpairs with phenotypic information for this phenotype was 
309, with a median of 0 sibpairs per family (range 0-5). The median number of 
generations with phenotypic information was 2 (range 1-4).  
We used the Pedigree Analysis Package (PAP), Version 5.0 [119] to perform 
segregation analysis. Under the mixed Mendelian model (model 1), the phenotype is 
influenced by a major gene, polygenic background and an untransmitted environmental 
component. The major gene is biallelic (A, a), with allele A, occurring at frequency p, 
associated with lower trait values. Mean values for the three genotypes (μAA, μAa, μaa, 
where the order of the means is constrained to be μAA ≤ μAa ≤ μaa) and a common 
standard deviation for all genotypes are estimated. Parent-to-offspring transmission 
probabilities for the three genotypes (τAA, τAa, and τaa) also are included in the model. τAA, 
τAa, and τaa designate the probability of transmitting allele A for the genotypes AA, Aa, 
and aa, with Mendelian expectations of 1, 0.5, 0, respectively. When the τ’s are set equal 
to p, there is no transmission of the major effect. Polygenic heritability (H) after 
accounting for the putative major gene effect was also estimated. For parent of origin 
models, heterozygotes who inherited A from their mother (Aa) and heterozygotes who 
inherited A from their father (aA) are distinguished from one another and allowed to have 
different means. Many of the free τ's models did not converge initially. In order to 
estimate these models, τAA and τaa were fixed to 1 and 0, respectively, and likelihoods 
calculated under these additional assumptions were used for the analysis.  
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 All parameters were estimated using a maximum likelihood method. Nested 
models representing null hypotheses were tested against a more general model using a 
LRT, in which the difference between negative twice the log-likelihood (-2 ln L) values 
for two models approximates a chi-square distribution with degrees of freedom equal to 
the number of independent parameter restrictions. The most parsimonious model of those 
not rejected by likelihood ratio test (p>0.01) was determined using AIC [120], which is 
computed as -2 ln L of the model plus twice the number of parameters estimated. The 
model with the lowest AIC indicates the most parsimonious fit to the observed data. 
To account for the ascertainment of the families, the likelihood of each model was 
conditioned on the likelihood of the proband’s phenotype under the model, an appropriate 
correction for the manner in which these families were extended [121]. While our 
criterion required 2 or more preterm first degree relatives for a family to be enrolled in 
the study, the ascertainment scheme is approximately equivalent to single ascertainment 
[122]. Because not all preterm deliveries in the metropolitan St. Louis or Finnish health 
care systems occurring during the study period were captured under our ascertainment 
scheme, the probability that a family was identified through multiple probands is small 
and should be proportional to the number of affected deliveries in a family, as expected 
under single ascertainment[123]. Under single ascertainment, conditioning on the 
proband’s phenotype is sufficient to adjust for the ascertainment of families [123]. Hence, 
analyses for infant’s gestational age were corrected for the proband infant’s gestational 
age jointly with PTB (<37 weeks) affection status. Similarly, analyses attributing 
gestational age to the mother were corrected for the proband mother’s average gestational 
age of children jointly with her PTB (<37 weeks) affection status.  
51
 To test genetic heterogeneity among races, we used the heterogeneity 
2
 test [110; 
111] in which the -2lnL value under the best fitting model for the combined data is 
subtracted from the summation of -2lnL values for stratified analyses to obtain the test 
statistic. This test statistic approximates a 
2
 distribution with df equal to K*J-K where J 
is the number of subgroups and K is the number of parameters in the model. 
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 Chapter 4: Considering rapidly evolving genes facilitates discovery of novel gene for 
PTB: follicle-stuimulating hormone receptor, FSHR 
§
 
 
Abstract  
The signals initiating parturition in humans have remained elusive, due to 
divergence in physiological mechanisms between humans and model organisms typically 
studied. Because of relatively large human head size and narrow birth canal cross-
sectional area compared to other primates, we hypothesized that genes involved in 
parturition have evolved rapidly along the human and/or higher primate phylogenetic 
lineages to decrease the length of gestation and alleviate complications arising from these 
constraints. Consistent with our hypothesis, many genes involved in reproduction show 
rapid evolution in their coding or adjacent noncoding regions. We screened >8,000 SNPs 
in 150 rapidly evolving genes in 165 Finnish preterm and 163 control mothers for 
association with PTB. A linkage disequilibrium block of SNPs in FSHR, rs11686474, 
rs11680730 and rs12473870, showed significant association across ethnically diverse 
populations. By considering rapid evolution, we identified a novel gene associated with 
PTB, FSHR. We anticipate other rapidly evolving genes will similarly be associated with 
PTB risk and elucidate essential pathways for human parturition. 
Introduction 
Because humans are born developmentally less mature than other mammals [124; 
125], birth timing mechanisms may differ between humans and model organisms that 
have been typically studied [126]. Evidence suggests that parturition has changed along 
the human lineage in response to other uniquely human adaptations. The dramatic 
                                                 
§
 This chapter is adapted from: Plunkett J, et al. Evolution History of FSHR in Humans 
Predicts Role in Birth Timing. Submitted. 
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 increase in brain size, along with the human pelvis becoming narrower to facilitate 
bipedalism, places unique constraints on birth in humans compared even with 
evolutionarily close relatives such as Neanderthals and chimpanzees [127; 128]. Given 
the historically high mortality rate associated with pregnancy, these human adaptations 
are likely to have generated a strong selective pressure to initiate parturition at a 
relatively earlier time in gestation compared to non-human primates to avoid 
cephalopelvic disproportion and arrested labor. High rates of human versus non-human 
primate divergence in human pregnancy-related genes, such as genes in the reproduction 
Gene Ontology (GO) category [129; 130] as well as GO categories related to fetal 
development, including transcription factors [131], nuclear hormone receptors [131], 
transcriptional regulation [132] and development [130], support the notion that human 
gestation length has been shortened to accommodate features unique to human 
pregnancy. As a result, the set of genes rapidly evolving on the human lineage likely 
includes genes that play important roles in regulating parturition and potentially influence 
PTB risk. 
Genetic influences on birth timing in humans appear to be substantial; however, 
association studies using candidates selected from suspected pathways have not detected 
robust susceptibility variants for PTB. Genome-wide association studies (GWAS) are 
promising but will require large numbers of well-characterized subjects in order to 
overcome the challenge of multiple statistical comparisons. To address these limitations, 
we applied an evolutionarily-motivated filter to examine genes showing marked 
divergence between humans and other mammals, defined by relative nucleotide 
substitution rates in coding and highly conserved noncoding regions, for association with 
61
 PTB. Here we show that genes with the signature of rapid evolution in humans provide 
an informative group of candidates, and demonstrate as proof of concept that one rapidly 
evolving gene, follicle-stimulating hormone receptor (FSHR), has significant association 
with PTB.  
Results and Discussion 
Life history traits. Because of large human head size and narrow birth canal 
cross-section compared to other primates [127], we hypothesized that genes involved in 
parturition have evolved rapidly along the human phylogenetic lineage to decrease the 
length of gestation and alleviate the complications arising from these constraints. We 
performed a comparative analysis of life history traits in mammals to further evaluate 
whether the relative gestational period in humans has decreased compared to other 
primates and mammals. Data acquired by Sacher and Staffeldt [133] and reanalyzed by 
us show that both adult and neonatal primates have higher brain to body weight ratios 
compared to other mammals (Figure 4.1A, B). The decoupling of brain/body size ratios 
in primates makes it possible to ask whether gestation in primates is linked to brain size 
or body size. Primates and other mammals have equivalent gestational periods with 
respect to brain weight (Figure 4.1C). In contrast, the gestational period in primates is 
longer relative to the length of gestation in mammals with equivalent neonatal body 
weights (Figure 4.1D). This suggests that the length of gestation is expected to change 
with brain size but not body size. 
Humans have evolved the highest adult brain to body weight ratio of any mammal 
[29]. In contrast to the evolution of brain/body ratios along the lineage leading to 
primates, the increase in the brain/body ratio along the lineage leading to humans is 
62
 present in adults but not neonates (Figure 4.1B). The simplest explanation is that adult 
brain/body ratios have changed independently of neonatal ratios. However, the ratio of 
brain/body weight is highest at birth and declines until adulthood. Thus, an alternative 
explanation is that both adult and neonatal brain/body ratios have increased in humans, as 
in primates, but that a concurrent decrease in the length of gestation lowered the neonatal 
brain/body ratio. This second possibility is supported by the relative immaturity of human 
neonates compared to other primates [124; 125] and that the length of human gestation, 
relative to either neonatal brain or body weight, is shorter than most other primates 
(Figure 4.1C,D). 
To examine the evolution of gestation length relative to neonatal brain and body 
weight in primates, we inferred the evolution of these characters across a phylogenetic 
tree. For both gestation-neonatal body ratio (Figure 4.2A) and gestation-neonatal brain 
ratio (Figure 4.2B) there is a consistent trend of a relatively shorter length of gestation on 
branches leading to humans. Of note, human has the lowest gestation-neonatal body ratio 
(Figure 4.2A) or gestation-neonatal brain ratio (Figure 4.2B) of all the 20 primates. The 
gestation-neonatal brain ratio for humans is 69% that of gorilla and 45% that of 
chimpanzee. The gestation-neonatal body ratio of human is 49% that of gorilla and 50% 
that of chimpanzee.  
Signature of rapid evolution. In light of this evidence for human adaptation for 
birth timing, we examined whether genes involved in parturition would display a 
signature of positive selection, an increased rate of amino acid altering to synonymous 
nucleotide substitutions (dN/dS; Figure 4.3). We found that, of 120 suggested candidate 
genes for PTB [134] that were included in ENSEMBL database, 7 showed statistically 
63
 significant increased rate acceleration (i.e. increased dN/dS; p<0.05) along the human 
lineage in comparison to the other lineages. Table 4.1 shows these 7 genes plus 2 
accelerated human genes significantly rapidly evolving along the human-chimpanzee 
ancestor lineage (complete analysis of dN/dS reported in [135; 136]). Of these, common 
variants of PGR [137] and MMP8 [138] have previously been found to contribute to PTB 
risk. Of note, this candidate gene list derived from the Institute of Medicine report on 
PTB [134], and information from the Gene Cards and Online Mendelian Inheritance in 
Man databases was relatively enriched for genes rapidly evolving along the human 
lineage compared to a normal distribution (3/120 expected; p=0.02) and exhibited a 
similar trend for enrichment in comparison to other human genes in the ENSEMBL 
database (408/10,440 observed with p<0.05; p=0.14 vs. suggested PTB candidates). 
Using criterion agnostic to possible involvement with PTB, and measuring genome-wide 
changes, we identified 175 genes either rapidly evolving along the human (40 genes) or 
on the human and human-chimpanzee ancestor lineages combined (135 genes) at a 5% 
false discovery rate (FDR) [139] from this analysis of protein-coding sequences.  
Motivated by this evidence of protein coding region evolution for genes involved 
in parturition and that positive selection has also been found to act on noncoding regions, 
we developed a method to identify rapidly evolving noncoding sequences [132; 140]. We 
identified a total of 401 elements significant along the human lineage and 2103 elements 
significant along the human and human-chimpanzee ancestor lineages at a 5% FDR. To 
choose candidate genes, we calculated gene-wise p-values for each gene locus by 
assigning each conserved element to its nearest RefSeq gene [141] and a Fisher’s 
combined p-value across the locus. This resulted in identification of a total of 279 
64
 candidate genes (complete analysis of rapidly evolving non-coding regions reported in 
[135; 136]). 150 of the genes identified as rapidly evolving in the protein-coding 
sequence and highly conserved noncoding elements screens, selected based on expression 
and functional information suggesting potential roles in parturition, were analyzed for 
association with PTB (Table 4.2). 
Association analysis of rapidly evolving genes. Because recent data suggests 
that heritability of risk of PTB acts largely or exclusively through the maternal genome 
[29; 30; 32] and the Finnish have low environmental risk and high genetic homogeneity 
compared to other populations, we genotyped Finnish (165 preterm, 163 control) mothers 
for 8,490 SNPs in the gene regions of our prioritized list of 150 rapidly evolving genes 
(Figure 4.4). The most significant finding was rs6741370 (p=9.28 x 10
-5
) in the follicle-
stimulating hormone (FSH) receptor gene (FSHR). 91 SNPs were significant at the 
p<0.01 level by allelic tests (Table 4.3). However, no SNPs were significant after 
correcting for 6,042 independent tests, considering relationships among markers, by the 
Bonferroni method (p<8.27 x 10
-6
). Of note, 8 of the 10 most statistically significant 
SNPs were located in FSHR. We identified FSHR as rapidly evolving in the noncoding 
analysis, with 40 changes in 4,218 bp of 17 conserved elements (human lineage p = 5.4 X 
10
-5
). Moreover, FSHR was revealed as rapidly evolving in a study of noncoding 
conserved elements by Prabhakar and colleagues [140], which otherwise had limited 
overlap with our gene list (see Methods). FSHR also harbors SNPs with extreme iHS 
values in the Yoruban population, reflecting extended haplotype homozygosity and 
suggesting a recent selective sweep [142]. Bird and colleagues [143] identified a region 
less than 1 megabase downstream of the FSHR gene boundaries as rapidly evolving in 
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 their study, further supporting rapid evolution of the locus. This information, together 
with the known importance of variation in human FSHR in subfertility [144; 145], a risk 
factor for preterm delivery independent of the use of assisted reproductive technologies 
[146; 147], and evidence suggesting its expression in uterus and cervix [148-150], 
motivated its specific study.  
16 SNPs in FSHR showing potential association in the screening analysis (p<0.1) 
were genotyped in US White (147 preterm, 157 control), US Black (79 preterm, 164 
controls) and US Hispanic (73 preterm, 292 control) mothers (Figure 4.5; Table 4.4). 
Several SNPs exhibited suggestive association (p<0.01) with PTB risk. One SNP in the 
US Blacks, rs12473815, was significant after correcting multiple testing (13 independent 
tests; p<0.004). The SNP rs12473815 is in high linkage disequilibrium (LD) with three 
nearby SNPs, rs11686474, rs11680730 and rs12473870 (Figure 4.5), all of which showed 
evidence of association across populations. Meta-analysis of these SNPs resulted in odds 
ratios ranging from 1.37 to 1.41 with a common 95% confidence interval of 1.26-1.50. Of 
note, when combining data from all populations tested by meta-analysis, p-values for 
rs11686474 (p=0.0006) and rs11680730 (p=0.002) are significant after a Bonferroni 
correction (p<0.003).  
In FSHR, 4 SNPs in high LD show evidence of association with PTB across the 
populations studied. These SNPs lie within intron 2 of FSHR (Figure 4.5) and show little 
LD with variants outside of this intron, based on available information from the 
International HapMap Project database [151]. Variants in this intron may tag yet 
uncharacterized variants in coding regions or nearby regulatory sequences. Alternatively, 
an intronic variant in FSHR may affect risk directly by altering functional sequences 
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 contained within the intron, such as microRNA binding sites, splice regulatory sites or 
transcription regulation sites. For instance, a variant in a splice enhancer site may change 
splicing patterns in favor of transcripts that promote PTB risk, as several alternatively 
spliced FSHR isoforms have been observed with altered function [152]. Risk-promoting 
variation in this gene likely contributes to birth timing, rather than size at birth, based on 
additional tests examining gestational age or birth-weight Z-score as a quantitative trait, 
rather than PTB affection status (Table 4.5). Hence, FSHR may represent a novel gene 
involved in birth timing and PTB risk. 
FSHR encodes the follicle-stimulating hormone (FSH) receptor. FSH is secreted 
from the pituitary and, in females, acts primarily on receptors in the ovaries to stimulate 
follicle development and synthesis of estrogens. Investigators also have observed FSHR 
protein and mRNA expression in nongonadal tissues, including uterus and cervix [148-
150]. In these tissues, FSHR may mediate uterine relaxation, as suggested by FSH’s 
ability to modify electrical signaling in the myometrium, independent of estrogen and 
progesterone [148]. Padmanabhan and colleagues [153] noted a progressive rise in 
bioactive serum FSH levels during pregnancy. Because high levels of FSH are known to 
downregulate FSHR expression [154], increasing levels of FSH may lead to gradual 
desensitization to the hormone and resultant increase in contractility as term approaches. 
Additionally, evidence from the FSHR haploinsufficient mouse [155] suggests that FSHR 
levels affect the relative abundance of progesterone receptor isoforms A (PR-A) and B 
(PR-B). Increased PR-A: PR-B ratios, occurring in human pregnancy normally near term 
and observed in FSHR haploinsufficient mice in non-pregnant states, are correlated with 
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 increased myometrium contractility. Hence, dysregulation of FSHR may contribute to 
early uterine contractility and promote PTB.  
Aspects of our approach pose limitations on interpretation of this work. First, we 
assigned conserved elements to the nearest RefSeq gene to calculate gene-wise p-values; 
however, conserved elements may not be associated with the nearest gene per se, 
potentially affecting the accuracy of the estimated gene-wise p-values. Additionally, 
because we use adjacent genes to estimate expected synonymous and nonsynonymous 
rates for a given locus, rapidly evolving genes that are located physically nearby other 
genes undergoing rapid evolution, such as gene families with multiple members in the 
same region, may miss detection. The variability in number of probes represented on the 
Affymetrix Genome-Wide Human SNP Array 6.0 within the gene regions of the 150 
rapidly evolving genes tested poses another limitation. Although the coverage is adequate 
for most rapidly evolving genes, there are some genes with too few probes tested to 
support or refute their potential association with PTB; as a result, this study may have 
failed to detect association between PTB and rapidly evolving genes underrepresented on 
this genotyping array. Lastly, while precedence exists for intronic variants affecting 
protein structure and function [156; 157], additional study is needed to determine whether 
any of the SNPs associated with PTB in this work has a functional effect. 
Overall, FSHR represents a likely candidate for involvement in PTB. Even though 
FSHR has a plausible role in parturition physiology, it has not been considered in 
previous association studies or appeared on candidate gene lists like that in the Institute 
of Medicine report on PTB [134]. Thus, by considering rapid evolution, we identified a 
gene associated with PTB that otherwise would not have been revealed by current models 
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 of parturition physiology. Moreover, our approach exploits an evolutionarily-motivated 
filter to more efficiently utilize currently available datasets for PTB, which are probably 
underpowered to detect variants of effect sizes reported in GWAS of other complex traits. 
Our approach represents an alternative method for a priori gene discovery in which fewer 
comparisons are made than in GWAS, thus potentially retaining more power to detect 
effect sizes typical for common variants. We anticipate that other rapidly evolving genes 
will similarly be associated with PTB risk and elucidate the essential pathways for human 
parturition. 
Materials and Methods 
Allometric Analysis. Data acquired by Sacher and Staffeldt [133] was used to 
examine the relationships among brain size, body size and gestation length among 
mammalian species. Specifically, we compared logarithm-transformed values for these 
traits between human, primate and non-primate mammals, using linear regression 
implemented in R [158]. Additionally, we used allometric data from this paper and the 
primate phylogeny delineated by Purvis [159] to trace the evolution of gestation-neonatal 
body size ratio, and gestation-neonatal brain size ratio, using Mesquite [160]. Given a 
phylogenic tree, the Mesquite method uses parsimony to reconstruct the ancestral states 
by assuming a squared change for a continuous character from state x to state y is (x-y)
2
. 
Coding sequence multiple sequence alignments. We obtained a set of 10,639 
human gene predictions from the ENSEMBL database with one-to-one orthologs in the 
chimpanzee, macaque, mouse, rat, dog, and cow genomes (Release 46) [161]. We limited 
our analysis to only those proteins where the human, chimpanzee, macaque, and at least 
75% of the mammalian genomes were present. To prevent spurious results arising from 
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 comparing different isoforms from different species, we compared all of the human gene 
models against all of the chimpanzee gene models by BLAST searches, keeping the pair 
with the highest percent identity (and longest gene model in case of tie). We then 
compared this human gene model against all of the models from the other species, 
finding the best match among the gene models in the other species. We generated a 
multiple sequence alignment using the MUSCLE algorithm [162] and reverse translated 
these alignments to generate nucleotide alignments. We limited our analysis to only those 
proteins where the human, chimpanzee, macaque, and at least 75% of the mammalian 
genomes were present. Chi-squared analysis was used to determine the statistical 
significance of observed and expected genes with p<0.05 in suggested PTB candidate and 
overall human gene lists. 
Noncoding sequence multiple sequence alignments. We obtained a set of 
highly conserved elements from UCSC Genome Browser [163]. In total, 443,061 
noncoding sequences with a conservation score >=400 were tested. Of these elements, 
34% overlapped coding sequence by at least one nucleotide and were excluded from the 
analysis. The remaining noncoding elements span 47 MB (approximately 1.5% of the 
genome). Therefore, these sequences represent only the most highly conserved noncoding 
sequences and not the entire 6% of the noncoding genome that is functionally constrained 
[164]. The median total branch length for these elements was 0.235, which is 1/4 the 
synonymous rate. Therefore, these are not perfectly conserved sequences, but they are 
evolving substantially slower than the neutral expectation. From the 17-way MultiZ 
alignments that are publicly available (downloaded March 2007) [165], we extracted the 
human, chimpanzee, macaque, mouse, rat, dog and cow sequences. We filtered this 
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 alignment set using two criteria. First, any alignment that contained 2 or more human 
homoplasies (the human nucleotide was equal to a conserved nucleotide in the 
mammalian outgroups, but different from the nucleotide shared between macaque and 
chimpanzee) were removed. Second, if the human sequence had a paralog with a percent 
difference less than twice the percent difference of the human-chimpanzee orthologs, 
then that sequence was excluded (e.g. if the human-chimpanzee sequences were 98% 
identical, the human paralog had to be less than 96% identical). This filter reduced the 
chance that a rapidly evolving human sequence was actually a misaligned paralog. 
Likelihood ratio tests. We used the phylogeny ( (Human, Chimpanzee), 
Macaque), ( (Mouse, Rat), (Dog, Cow))). The evolutionary models were implemented in 
the HYPHY package [166] and we used the Q-value software [139] to establish 
statistical thresholds to achieve 5% false discovery rates (p-value distributions and pi_0 
values in Figure 4.6). HYPHY creates a molecular evolution programming language, 
enabling comparison of multiple evolutionary models and phylogenies. The source code 
and documentation of the HYPHY tests is available from the Fay Laboratory.  
For both tests, the alternative model has one additional degree of freedom and the 
significance of the change in likelihood was determined using 
2 
 statistics. Both models 
use adjacent coding or conserved noncoding sequences to estimate the expectation for a 
given sequence that accounts for variable mutation rates across the genome as well as 
lineage-specific differences in effective population size by allowing for branch-specific 
differences in selective constraint. For the coding sequence, we used 20 adjacent genes, 
ten upstream and downstream when possible, to estimate the expected synonymous rate 
and average constraints on each lineage. Twenty genes were used because the 
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 synonymous rate does vary across the genome in windows of approximately 10 MB 
[167]. For noncoding sequences, we concatenated blocks of 25 kb of conserved 
noncoding sequence. These blocks typically spanned about 1 MB of the genome. Each 
element in the middle 50% of the window was tested against the expectation for that 
window to limit edge effect. The window was then advanced to the element at the 50% 
percentile of the window.  
Previous studies of both coding [9, 46] and noncoding [11, 21] sequences identify 
regions evolving under positive selection by a rate of evolution faster than a neutral rate. 
However, we felt that this criterion is too restrictive since some genes may have an 
increased rate of evolution along the human lineage relative to other mammals, but not 
increased above the neutral rate. To include genes with a significantly increased rate in 
humans compared to other mammals for testing in a population association study, we 
identify genes as rapidly evolving by testing whether omega along the human (or 
human+human-chimpanzee ancestor) lineage is significantly higher than omega along the 
non-human lineages (or non-human+non-human-chimpanzee ancestor). Here, omega is 
dN/dS-adj or dNC/dNC-adj, where dNC is the noncoding rate and dS-adj and dNC-adj 
are the adjacent synonymous rates from the 10 upstream and 10 downstream genes and 
the adjacent noncoding rates from 25 kb of conserved noncoding sequences, respectively. 
Thus, we test whether the data is more likely under a model with 1 omega value or 2 
omega values (Figure 4.3). The coding sequence model used the MG94xHKY85 [168] 
model of codon evolution. The noncoding sequences model used an HKY85 model. We 
calculated gene-wise p-values for each gene locus by assigning each conserved element 
to its nearest RefSeq gene [141] and a Fisher’s combined p-value across the locus. Chi-
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 squared analysis was used to determine the statistical significance of observed and 
expected genes with p<0.05 in suggested PTB candidate and overall human gene lists. 
Comparisons with published studies of rapid evolution. The following data 
was extracted from published studies for comparison with results from our coding 
analysis: genes with p<0.01 for test of dN/dS>1 from Nielson et al. [46]; genes with 
p<0.01 for test of dN>dS on human lineage Clark et al. [9]; genes with adjusted p<0.05 
for test of 1 omega versus 2 omegas (i.e. 1 on human lineage, 1 for other species) Arbiza 
et al [48]. For comparison with results from our noncoding analysis, we compared closest 
genes to human accelerated regions listed in Table S7 of Pollard et al. [11] and closest 
genes to regions in listed in Table S1 of Prabhakar et al [21]. Ensembl gene identification 
numbers and/or HUGO Gene Nomenclature Committee (HGNC) gene symbols, as 
available, were compared among studies to determine the degree of overlap. The Venny 
[169] online tool was used to visually represent the degree of overlap among studies as 
Venn diagrams (Figures 4.7 and 4.8).  
Our list of rapidly evolving coding region gene list showed low overlap with 
previous studies that required for dN/dS > 1 in their analyses (6% with Clark et al. [130], 
0% Nielson et al. [170]) and more overlap with Arbiza et al. [171] (26%), which 
considered rate acceleration on the human lineage by methods more similar to ours than 
those used by [130; 170] (Figure 4.7). For rapidly evolving conserved noncoding 
elements in humans, 22% of the elements we identified were in common with Prabhakar 
et al. [140]. Considering unique genes associated with rapidly evolving conserved 
noncoding elements in humans, 11% of our genes also were identified by Prabhakar et al. 
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 [140], and 4% identified by Pollard et al. [132]. Similar to our study, 4% of unique genes 
in the Prabhakar study overlapped with those identified by Pollard et al. (Figure 4.8).  
Candidate rapidly evolving gene list. To minimize the number of tests we 
would perform and thereby retain more power to detect small effects, we selected a 
subset of genes likely to be involved in parturition, based on expression and functional 
information, to use as candidate genes. A candidate gene list was developed using genes 
identified as rapidly evolving from following categories: 10% FDR human lineage from 
coding screen, 10% FDR human lineage from noncoding screen and 5% FDR human-
chimpanzee lineage from coding screen. A total of 742 genes are included in this 
comprehensive list of rapidly evolving genes. To minimize the number of tests we would 
perform and thereby retain more power to detect small effects, we selected a subset of 
genes likely to be involved in parturition, based on expression and functional 
information, to use as candidate genes. Genes were included as candidates if at least 2 of 
3 conditions met: had a GO term suggesting possible biological role in parturition (e.g. 
extracellular matrix, calcium ion, DNA-binding/transcription, intracellular signaling, cell 
fate/apoptosis, cell growth); were previously identified as candidate gene; had expression 
included relevant tissues (e.g. uterus, placenta, brain) documented in Unigene [172]. 
Duplicated genes from a list developed by Bailey and colleagues [173] that were 
identified as pregnancy, fetal, placental or hormone-related genes were also included as 
candidates. A total of 150 of genes were used as candidate genes in subsequent analysis 
(Table 4.2). 
Human Subjects. Mothers of preterm or term infants were enrolled for genetic 
analysis by methods approved by Institutional Review Boards/Ethics Committees at each 
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 participating institution. Informed consent was obtained for all participants. Mothers with 
PTB were included if the birth was spontaneous (non-iatrogenic), singleton, had no 
obvious precipitating stimulus (trauma, infection, drug use), and was less the 37 weeks 
(Yale University; New York University) or 36 weeks (University of Helsinki; University 
of Oulu; Centennial Hospital, Nashville, TN) of completed gestation. DNA from blood or 
saliva was prepared by standard methods. Race/ethnicity was assigned by self-report. For 
the US Black cohort, no differences in were found in the distribution of 24 ancestry 
informative markers selected across the genome comparing cases and controls (data not 
shown). All specimens were linked with demographic and medical data abstracted from 
maternal/neonatal records.  
Genotyping. Initial genotyping of the Finnish cohort was performed using the 
Affymetrix® Genome-Wide Human SNP Array 6.0. Genotypes were called from cell 
intensity data by the birdseed v2 algorithm, implemented in Affymetrix® Genotyping 
Console 3.0. Of 428 SNP 6.0 arrays available for analysis, only 392 samples had their 
raw intensity data converted to genotype calls using the birdseed v2 algorithm in 
Affymetrix Genotype Console 3.0, after poor quality chips (i.e. “out of bounds” 
designation or XY gender call by Genotyping Console) were excluded. We selected 
SNPs within the gene regions, defined as 5 kilobases (kb) upstream to 5 kb downstream 
of the most inclusive gene boundaries between those listed for the longest transcript 
documented in the Ensembl database and those defined in our comparative genomic 
analysis, of our 171 rapidly evolving candidate genes for analysis. A total of 12,444 
SNPs were located within our rapidly evolving genes. The gene coverage ranged from 0-
900 SNPs/gene region, with a median of 13 SNPs/gene region. 11 genes had no SNPs in 
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 the gene region represented on the SNP 6.0 array. Genotyping for additional analysis of 
the Finnish cohort and replication analysis was performed using the Sequenom iPLEX 
massARRAY technology (Sequenom, San Diego, CA). 
Finnish cohort analysis. Data cleaning was performed with the Whole-genome 
Association Study Pipeline (WASP) software package [174] and PLINK [175]. An 
additional 6 individuals were excluded because of possible cryptic relatedness, as 
suggested by their presence in IBS distance-defined clusters far from the rest of the 
genotyped subjects. 58 individuals were removed due to a high genotype missing rate for 
the SNPs of interest (i.e. <95% call rate), leaving a total of 165 preterm and 163 control 
mothers in the final analysis. Of 12,444 SNPs selected, 9,610 SNPs were used in the final 
analysis after removing SNPs not in Hardy-Weinberg Equilibrium in controls (p<0.001), 
<95% genotype call rate, with minor allele frequency<0.05 or were duplicate probes. 
Allelic (
2
, df 1) and genotypic (
2
, df 2) tests for association, LD measures and odds 
ratios were estimated for each cohort using WASP and/or PLINK. Our primary analysis 
considered PTB affection status (i.e. delivery <36 weeks) as a binary trait, comparing 
allele and genotype frequencies between case and control groups by 
2 
test. We also 
examined gestational age and birth-weight Z-score as quantitative traits, standardized to 
normal distributions ( =0, =1) using a Wald test to compare the mean phenotype 
between different allele or genotype classes. 
A variety of measures were taken to ensure that results from these test were 
explained by true associations. First, genomic control measures of population 
substructure ( =1.07) indicated little inflation of statistics due to substructure. Correction 
for IBS clustering to bring  to 1 resulted in the same SNPs being found as most 
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 significantly associated, suggesting that whatever minor population substructure may 
exist does not explain the association findings. Confounding of the results due to 
genotyping batch or location effects was not observed. Furthermore, minor allele 
frequencies observed in controls were generally consistent with HapMap estimates for 
Caucasians. As some SNPs are expected to show significant association with PTB by 
chance due to the large number of tests we are performing, we corrected for multiple 
testing using the simpleM method [176], which estimates the number of independent 
tests, given the LD relationships among SNPs, used to adjust the significance level. 
Extension of genotyping in Finnish cohort. Because FSHR showed evidence of 
enrichment of significant p-values as well as representing a plausible agent in parturition, 
we chose to examine the genes in greater depth. Of the 149 SNPs tested in FSHR in the 
Affymetrix analysis, 22 showed evidence of association (p<0.01) in the SNP 6.0 analysis 
and 9 were genotyped with the Sequenom technology for cross-platform validation. SNP 
genotypes showed high degree of concordance across platforms (~98%) and association 
results were consistent.  
To increase coverage, we genotyped an additional 42 SNPs spanning the FSHR 
gene region in a subset of the Finnish cohort (n= 105 preterm, 95 control mothers) based 
on DNA availability and quality. For SNP selection, data from the HapMap CEU 
population was examined in the Haploview program [177], using tagger and haplotype 
block functions, to identify regions of high LD. We selected 1 SNP per haplotype block, 
defined using the D’ confidence interval method [178], having the highest minor allele 
frequency (MAF) in the CEU population for genotyping. We also included coding SNPs 
and SNPs to improve coverage of conserved elements contributing to the gene’s 
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 designation as “rapidly evolving.” This selection scheme resulted in approximately 20-
30% coverage of the gene region at r
2≥0.8. Data cleaning and analysis was conducted as 
described above. In total, 40 SNPs met quality control standards (Hardy-Weinberg 
Equilibrium in controls p>0.001, >95% call rate, MAF>0.01) and were analyzed. Of the 
SNPs genotyped to increase coverage, those that showed suggestive association (p<0.1; 
n=16) were examined further. 
Replication Analysis. 16 SNPs in FSHR showing potential association in the 
screening analysis (p<0.1) were genotyped in US White (147 preterm, 157 control), US 
Black (79 preterm, 164 controls) and US Hispanic (73 preterm, 292 control) mothers 
(Figure 4.4; Table 4.4). Data cleaning and analysis was performed as described above. 
Meta-analysis of data for significant SNPs was done using the Mantel-Haenszel method, 
after successfully passing the test of homogeneity.  
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Figure 4.1. Allometric analysis of brain size, body size, and gestational length by 
linear regression. 
 
Brain to body weight ratios for adults (A) and neonates (B) are shown for humans (red), 
other primates (blue), and other mammals (black). The black line shows least squares fits 
to the 91 mammalian species. Neonatal brain (C) and body size (D) to gestational time 
ratios are displayed for the same species. The blue line shows least squares fits to 15 
primate species. Allometric data was acquired by Sacher and Staffeldt (1974). 
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Figure 4.2A. Phylogenetic analysis of brain size, body size, and gestational length in 
primates. 
 
Gestational time to neonatal brain size natural logarithm-transformed ratios are shown for each species and 
color coded along each lineage as inferred by parsimony. Allometric data was acquired by Sacher and 
Staffeldt (1974) and phylogeny by Purvis (1995)   
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Figure 4.2B. Phylogenetic analysis of brain size, body size, and gestational length in 
primates. 
 
Gestational time to neonatal body size natural logarithm-transformed ratios are shown for each species and 
color coded along each lineage as inferred by parsimony. Allometric data was acquired by Sacher and 
Staffeldt (1974) and phylogeny by Purvis (1995) . 
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Figure 4.4. Flowchart representing study design for testing association of rapidly 
evolving genes with preterm birth. 
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Figure 4.6: Distributions of p-values for coding and noncoding screens used to 
determine false discovery rate thresholds for significance. 
 
 
Panel A depicts the distribution of p-values for test for significant rate acceleration on 
human lineage compared to other mammalian lineages for coding sequences. Panel B 
depicts the distribution of p-values for test for significant rate acceleration on human-
chimpanzee lineage compared to other mammalian lineages for coding sequences. Panel 
C depicts the distribution of gene-wise p-values for test for significant rate acceleration 
on human lineage compared to other mammalian lineages for noncoding sequences. 
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Figure 4.7: Venn diagram illustrating the overlap between the results of our coding 
analysis and similar studies. 
 
 
 
Genes identified by Arbiza et al. (2006), Clark et al. (2003), Nielson et al. (2005) are 
compared to genes we identified as rapidly evolving on the human lineage (10% FDR, 
Panel A) or on the human+human-chimpanzee ancestor lineage (5% FDR, Panel B). 
Panel C depicts the overlap between genes we identified as rapidly evolving on the 
human lineage (10% FDR) or on the human+human-chimpanzee ancestor lineage (5% 
FDR). 
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Table 4.2: Candidate rapidly evolving genes examined for association with preterm 
birth. 
 
Gene Ensembl ID Chromosome Gene region 
start (bp)
A
 
Gene region 
stop (bp) 
ENSG00000187980 PLA2G2C 1 20,358,071 20,379,247 
ENSG00000054118 THRAP3 1 36,457,626 36,547,744 
ENSG00000197587 DMBX1 1 46,693,885 46,769,955 
ENSG00000134245 WNT2B 1 112,804,363 112,872,035 
ENSG00000163554 SPTA1 1 156,842,020 156,928,130 
ENSG00000133055 MYBPH 1 201,398,562 201,416,565 
ENSG00000133063 CHIT1 1 201,436,600 201,496,865 
ENSG00000117335 CD46 1 205,987,025 206,040,481 
ENSG00000162814 SPATA17 1 215,879,672 216,238,784 
ENSG00000143771 CNIH4 1 222,606,183 222,638,777 
ENSG00000183814 LIN9 1 224,480,481 224,577,619 
ENSG00000084674 APOB 2 21,072,806 21,334,249 
ENSG00000170820 FSHR 2 48,936,801 49,262,724 
ENSG00000028116 VRK2 2 57,432,980 58,284,303 
ENSG00000168758 SEMA4C 2 96,884,204 96,905,699 
ENSG00000196228 SULT1C3 2 108,123,399 108,265,257 
ENSG00000125571 IL1F7 2 113,382,017 113,412,506 
ENSG00000183840 GPR39 2 132,885,617 133,125,602 
ENSG00000169554 ZEB2 2 144,811,277 145,811,772 
ENSG00000183091 NEB 2 152,045,110 152,304,406 
ENSG00000138399 FASTKD1 2 170,089,515 170,147,595 
ENSG00000138435 CHRNA1 2 175,316,097 175,359,048 
ENSG00000064933 PMS1 2 190,352,355 190,508,863 
ENSG00000013441 CLK1 2 201,411,164 201,442,667 
ENSG00000116117 PARD3B 2 204,824,164 206,193,781 
ENSG00000163283 ALPP 2 232,931,318 232,959,619 
ENSG00000163286 ALPPL2 2 232,975,096 233,011,310 
ENSG00000157985 CENTG2 2 235,971,127 236,715,338 
ENSG00000168387 ASB14 3 57,252,242 57,297,334 
ENSG00000189283 FHIT 3 59,361,681 60,575,887 
ENSG00000196353 CPNE4 3 132,731,274 133,593,392 
ENSG00000169744 LDB2 4 15,988,937 16,703,648 
ENSG00000145241 CENPC1  4 68,015,584 68,104,114 
ENSG00000083857 FAT 4 187,740,918 188,341,814 
ENSG00000205096 DUX4_HUMAN 4 191,214,485 191,232,642 
ENSG00000174358 SLC6A19 5 1,249,710 1,281,385 
ENSG00000171540 OTP 5 76,948,651 76,999,618 
ENSG00000164292 RHOBTB3 5 95,087,606 95,162,827 
ENSG00000170482 SLC23A1 5 138,722,343 138,751,981 
ENSG00000204956 PCDHGA1 5 140,685,388 140,698,003 
89
ENSG00000173210 ABLIM3 5 148,496,326 148,625,192 
ENSG00000065029 ZNF76 6 35,330,427 35,376,740 
ENSG00000180872 DEFB112 6 50,131,694 50,461,861 
ENSG00000135346 CGA 6 87,847,192 87,893,643 
ENSG00000164520 RAET1E 6 150,246,014 150,258,863 
ENSG00000048052 HDAC9 7 18,279,517 19,021,186 
ENSG00000196335 STK31 7 23,711,404 23,843,843 
ENSG00000105954 NPVF 7 25,213,311 25,256,794 
ENSG00000091138 SLC26A3 7 107,188,393 107,275,261 
ENSG00000178234 GALNT11 7 151,348,797 151,463,085 
ENSG00000156006 NAT2 8 18,280,063 18,341,561 
ENSG00000120907 ADRA1A 8 26,662,251 26,968,234 
ENSG00000198363 ASPH 8 62,573,374 63,945,182 
ENSG00000064218 DMRT3 9 961,964 986,732 
ENSG00000153707 PTPRD 9 8,145,485 10,571,307 
ENSG00000106829 TLE4 9 81,284,764 81,955,007 
ENSG00000156345 CCRK 9 89,766,183 89,784,487 
ENSG00000182752 PAPPA 9 117,840,886 118,209,421 
ENSG00000167123 CEECAM1 9 130,201,775 130,253,724 
ENSG00000165997 ARL5B 10 18,983,319 19,274,735 
ENSG00000095794 CREM 10 35,450,807 35,546,892 
ENSG00000165731 RET 10 42,796,962 42,950,850 
ENSG00000095587 TLL2 10 98,109,356 98,268,658 
ENSG00000166407 LMO1 11 8,197,433 8,345,763 
ENSG00000166961 MGC35295 11 60,276,052 60,305,780 
ENSG00000149021 SCGB1A1 11 61,938,099 62,054,461 
ENSG00000173153 ESRRA 11 63,824,620 63,845,786 
ENSG00000204571 KRTAP5-11 11 70,963,408 70,987,532 
ENSG00000118113 MMP8 11 102,083,599 102,105,868 
ENSG00000204403 CASP12 11 103,980,451 104,254,354 
ENSG00000137713 PPP2R1B 11 111,097,898 111,156,373 
ENSG00000064309 CDON 11 125,320,174 125,512,554 
ENSG00000111266 DUSP16 12 12,513,420 12,632,500 
ENSG00000123360 PDE1B 12 53,224,671 53,264,290 
ENSG00000110958 PTGES3 12 55,338,379 55,373,318 
ENSG00000151846 PABPC3 13 24,563,276 24,575,705 
ENSG00000150893 FREM2 13 38,058,234 38,379,883 
ENSG00000174126 ENSG00000174126 13 40,907,081 40,917,746 
ENSG00000139842 CUL4A 13 112,906,151 112,984,825 
ENSG00000092054 MYH7 14 22,947,820 22,987,727 
ENSG00000196792 STRN3 14 30,427,761 30,570,340 
ENSG00000151322 NPAS3 14 32,428,709 33,386,974 
ENSG00000136352 NKX2-1 14 35,997,916 36,065,064 
ENSG00000198807 PAX9 14 36,195,877 36,683,420 
ENSG00000184302 SIX6 14 60,034,147 60,062,098 
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ENSG00000140009 ESR2 14 63,556,569 63,824,462 
ENSG00000100815 TRIP11 14 91,500,614 91,581,139 
ENSG00000182256 GABRG3 15 24,794,429 25,456,729 
ENSG00000198838 RYR3 15 31,385,469 31,950,591 
ENSG00000154237 LRRK1 15 99,271,983 99,432,838 
ENSG00000131650 KREMEN2 16 2,949,218 2,963,381 
ENSG00000183632 TP53TG3 16 32,546,984 32,574,764 
ENSG00000102962 CCL22 16 55,930,968 55,962,600 
ENSG00000050820 BCAR1 16 73,815,429 73,864,452 
ENSG00000186153 WWOX 16 76,653,469 77,833,566 
ENSG00000070444 MNT 17 2,229,115 2,256,834 
ENSG00000006047 YBX2 17 7,127,322 7,143,598 
ENSG00000133020 MYH8 17 10,229,495 10,271,188 
ENSG00000141048 MYH4 17 10,280,658 10,318,846 
ENSG00000125414 MYH2 17 10,360,323 10,433,169 
ENSG00000176160 HSF5 17 53,847,530 53,925,744 
ENSG00000213218 CSH3 17 59,298,106 59,309,848 
ENSG00000136488 CSH2 17 59,298,288 59,332,647 
ENSG00000136487 GH2 17 59,306,304 59,317,955 
ENSG00000189162 CSH1 17 59,343,295 59,354,930 
ENSG00000171634 BPTF 17 63,206,700 63,416,200 
ENSG00000089685 BIRC5 17 73,714,361 73,738,310 
ENSG00000181409 AATK 17 76,700,703 76,759,467 
ENSG00000186765 FSCN2 17 77,105,153 77,119,582 
ENSG00000101605 MYOM1 18 3,051,806 3,215,106 
ENSG00000101489 BRUNOL4 18 33,072,000 34,124,249 
ENSG00000133313 CNDP2 18 70,309,577 70,344,336 
ENSG00000131196 NFATC1 18 75,266,605 75,440,665 
ENSG00000174837 EMR1 19 6,833,582 6,908,102 
ENSG00000132024 CC2D1A 19 13,873,014 13,907,691 
ENSG00000127507 EMR2 19 14,699,205 14,755,353 
ENSG00000189231 PSG3 19 47,912,635 47,941,508 
ENSG00000131113 PSG1 19 48,044,852 48,080,711 
ENSG00000170848 PSG6 19 48,093,080 48,118,883 
ENSG00000170853 PSG11 19 48,198,649 48,227,471 
ENSG00000124435 PSG2 19 48,255,202 48,283,665 
ENSG00000204941 PSG4 19 48,358,736 48,406,630 
ENSG00000008438 PGLYRP1 19 51,209,255 51,223,144 
ENSG00000105499 PLA2G4C 19 53,237,916 53,310,865 
ENSG00000104826 LHB 19 54,206,049 54,217,159 
ENSG00000104827 CGHB_HUMAN  19 54,212,940 54,224,444 
ENSG00000189052 CGHB_HUMAN  19 54,233,875 54,245,378 
ENSG00000213030 CGB 19 54,237,709 54,249,212 
ENSG00000196337 CGB7 19 54,244,344 54,258,929 
ENSG00000171101 SIGLECP3 19 56,357,397 56,395,399 
91
ENSG00000131848 ZSCAN5 19 61,415,347 61,576,564 
ENSG00000125780 TGM3 20 2,216,426 2,274,202 
ENSG00000101452 DHX35 20 37,019,406 37,243,569 
ENSG00000064655 EYA2 20 44,941,086 45,255,897 
ENSG00000101181 GTPBP5 20 60,186,496 60,216,218 
ENSG00000060491 OGFR 20 60,901,622 60,920,797 
ENSG00000154640 BTG3 21 17,882,811 17,949,761 
ENSG00000157554 ERG 21 38,670,792 38,990,795 
ENSG00000100302 RASD2 22 34,223,536 34,284,987 
ENSG00000188677 PARVB 22 42,721,506 42,901,434 
 
A
 Positions refer to NCBI36 (hg18, March 2006 assembly) build of the human genome. 
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 Chapter 5: Association of cystolic phospholipase A2 gamma, PLA2G4C, with PTB risk
**
 
 
 
Abstract  
Correlating differences in genomic sequences with differences in reproductive 
physiology across species may led to new insights into mechanisms underlying birth 
timing. PLA2G4C, a phospholipase A isoform involved in prostaglandin synthesis, 
emerged from a comparative genomics screen of highly conserved noncoding elements as 
rapidly evolving in humans. Detailed structural and phylogenic analysis of PLA2G4C 
suggested a short genomic element within the gene duplicated from a paralogous highly 
conserved element on chromosome 1 specifically in primates. To examine whether this 
gene demonstrating primate-specific evolution was associated with birth timing, we 
genotyped common variation in PLA2G4C in US Hispanic (n= 73 preterm, 292 control), 
US White (n= 147 preterm, 157 control) and US Black (n= 79 preterm, 166 control) 
mothers. SNPs rs8110925 and rs2307276 in US Hispanics and rs11564620 in US Whites 
were significant after correcting for multiple tests (p<0.004). Additionally, rs11564620 
(Thr360Pro) was associated with increased metabolite levels of the prostaglandin 
thromboxane in healthy individuals (p=0.02), suggesting this variant may affect 
PLA2G4C activity. Association findings suggest variation in PLA2G4C gene may 
influence PTB risk by increasing levels of prostaglandins, which are known to regulate 
labor.  
 
                                                 
**
 This chapter is adapted from: Plunkett J, et al. Primate-specific evolution of noncoding 
element insertion into PLA2G4C and human preterm birth. In preparation. 
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 Introduction 
A growing body of evidence supports genetic influences on PTB risk; however, 
few genes have been consistently associated with the disorder [179; 180]. Investigators 
have typically focused on candidate genes selected based on predicted parturition 
physiology; however, this approach may be limited by the divergence in physiological 
mechanisms between humans and model organisms that have been typically studied. For 
example, while a rapid decline in progesterone plays a prominent role in initiating 
parturition in rodents and sheep, this signal does not seem to precede human labor [181]. 
Other parturition-related traits, such as placental morphology and source of progesterone, 
also differ importantly in humans compared to model organisms typically studied and 
may limit what generalizations can be made [181]. 
Differences in parturition physiology between apes, including humans, and other 
mammals may have developed in response to uniquely human adaptations including 
relatively large human head size and narrow birth canal cross-sectional area [127]. Genes 
involved in parturition likely have evolved differentially along the human and/or higher 
primate phylogenetic lineages to decrease the length of gestation and alleviate the 
complications arising from these constraints. As a result, the set of genes rapidly evolving 
on the human and/or higher primate lineage likely includes genes that play important 
roles in regulating parturition and potentially influence PTB risk. Consistent with our 
hypothesis, we identified FSHR as rapidly evolving by nucleotide substitution and as 
associated with PTB risk across independent populations [136]. 
In addition to nucleotide substitution, genomic rearrangements account for an 
important portion of genomic divergence among species. For example, Frazer et al. [182] 
108
 and Wetterbom et al. [183] observed insertions and deletions frequently when comparing 
genome sequences among humans, chimpanzees and other primate species. Moreover, 
these rearrangements may account for a larger fraction of genomic divergence than 
nucleotide substitutions [183]. Rearrangements can lead to loss or acquisition of exons, 
splice sites and promoters, facilitating differences in expression patterns, such as those 
observed for transcript variants of CHRM3 and SFTPB with differing transposable 
element insertion events [184; 185]. Hence, genomic rearrangement may contribute to 
rapid evolution along the human and/or higher primate lineages in response to unique 
physiological constraints.  
We hypothesize that genes with genomic rearrangements from the ancestral state 
occurring on the human and/or higher primate lineages may play important roles in birth 
timing and preterm delivery. Here, we examine common variants in a gene, PLA2G4C, in 
which we have identified a primate-specific insertion event and whose expression in the 
uterus [186] and role in prostaglandin synthesis suggest a potential role in parturition, for 
association with PTB. 
 
Results 
Evolutionary history of a primate-specific PLA2G4C noncoding element. We 
identified genes showing evidence of rapid evolution along the human lineage, based on 
evidence from a comparative genomic screen of highly conserved noncoding elements as 
described in [136]. Among the rapidly evolving genes emerging from our noncoding 
screen, PLA2G4C was identified as the most statistically significant gene (human lineage 
p=2.2x10
-7
, significant at 10% False Discovery Rate threshold) that was also included in 
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 a list of PTB candidate genes [134]. Because the reported deletion of PLA2G4C in cattle 
[187] contrasted with its presence in the 17-way MultiZ alignments [165] we used to 
identify the gene as rapidly evolving (Figure 5.1A), we examined the history of this 
region in greater depth. We compared sequence surrounding the 130 basepair (bp) highly 
conserved noncoding element in intron 14 of PLA2G4C on chromosome 19q13.3, which 
strongly motivated the gene’s designation as rapidly evolving along the human lineage, to 
other mammalian and primate genomes. From such comparisons, we determined that this 
130 bp element on human chromosome 19 was highly similar to a highly conserved 
noncoding element on human chromosome 1 (BLASTN 114/130 bp identical (87%), 
BLAST expect value= 5x10
-38
; Figure 5.1B). Subsequent analysis showed the MultiZ 
alignments we used in our comparative genomics screen had misaligned the human 
chromosome 19 element with sequences in other mammals which were orthologous to 
human chromosome 1. When appropriate alignments were examined, we observed that 
the human chromosome 19 element was nearly identical in higher primate species 
(chimpanzee, gorilla, orangutan, macaque) examined, but, absent in syntenic sequences 
in lower primates (lemur, bushbaby, tarsier) and other mammalian species. Chromosome 
1 elements from higher primates are more similar to lower primates and other 
mammalian species than chromosome 19 elements (Figure 5.2). The chromosome 1 
element occurs in the 5’ untranslated region of RNF11, a gene involved in inflammatory 
signaling, as it does in mouse.  Thus, a duplication of chromosome 1 noncoding element 
to chromosome 19 likely occurred before the last common ancestor between apes and 
macaque. A phylogenetic tree of coding sequences for PLA2G4C follows the expected 
mammalian phylogeny (Figure 5.3), suggesting that the duplication did not include 
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 coding sequences. Together these results suggest that neither element would qualify as 
rapidly evolving along the human lineage due to nucleotide substitution, but, the 
chromosome 19 element may represent a primate-specific change meriting further study. 
Association with preterm birth. Because of recent data that suggests heritability 
of risk of PTB acts largely or exclusively through the maternal genome [29; 30; 32], we 
genotyped US Hispanic (73 preterm, 292 control), US Whites (n= 147 preterm, 157 
control) and US Blacks (n= 79 preterm, 166 control) mothers for 14 SNPs in the 
PLA2G4C gene region (Table 5.1). The results from these analyses, reported in Table 5.2, 
include two SNPs, rs8110925 and rs2307276, in the US Hispanics and one in the US 
Whites, rs11564620, that were significant after correcting for 14 tests (p<0.004). The 
direction of effect was generally consistent across populations for these SNPs, as noted in 
Table 5.2. Meta-analysis p-values for SNPs rs8110925, rs2307276, and rs11564620 were 
also statistically significant after correcting for 14 tests (p<0.004; Figure 5.4).  
Additionally, 2, 3 and 4 SNP haplotypes containing SNPs rs8110925 and 
rs2307276 were significant in the US Hispanics after correcting for 18 haplotype 
comparisons (p<0.003), although not more significant than single SNP association 
findings (Table 5.3). 2 SNP haplotypes containing rs11564620 were moderately 
significant (p<0.05) in US Whites (Table 5.3). Linkage disequilibrium (LD) among SNPs 
rs8110925, rs2307276, and rs11564620 was very low (r
2
<0.1) in the three populations 
studied (Figure 5.5), suggesting multiple independent associations were observed. 
Association with prostaglandin concentrations. To test the potential functional 
effect of associated PLA2G4C variants on prostaglandin metabolism, we compared levels 
of metabolites of prostaglandin E2 (PGE), prostaglandin I2 (PGI) and thromboxane (11-
111
 DTXB2) among genotype classes for associated SNPs rs8110925, rs2307276, and 
rs11564620 in healthy individuals using a two-sided Wald test (Table 5.4). Of note, 
rs11564620, a nonsynonymous coding polymorphism, is associated with 11-DTXB2 
levels (p=0.04) despite the limited sample size available. The minor allele of rs11564620, 
present at approximately 10% frequency in US Whites, is associated with both risk for 
PTB and higher 11-DTXB2 levels (Wilcoxon one-sided p=0.02; Figure 5.6).  
 
Discussion 
Genomic analysis of PLA2G4C indicated that the conserved element which 
brought the gene to our attention was highly similar to a conserved element on human 
chromosome 1. Further study suggested that the conserved element on chromosome 1 
was duplicated to chromosome 19 along the primate lineage. As a result, human 
chromosome 19 noncoding element in intron 14 of PLA2G4C seems to represent a 
primate-specific change involving amplification and subsequent divergence rather than a 
region of increased nucleotide substitution, per se. We propose this duplicated element 
insertion represents a primate-specific change with a potential regulatory role in human 
parturition. 
Single SNP and haplotype association results implicate the role of SNPs 
rs8110925, rs2307276, and rs11564620 in conferring PTB risk (Tables 5.2 and 5.3). The 
associated SNPs are located in an 8 kilobase (kb) region of the 3’ end of PLA2G4C, near 
the genomic element of interest (Figure 5.7), but show little LD with each other (Figure 
5.5) or other SNPs in PLA2G4C documented in the International HapMap Project 
database [151]. Of note, Polyphen [188] and SIFT [189] programs predict rs11564620, a 
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 nonsynonymous polymorphism in exon 13 resulting in a change in amino acid 360 from 
threonine to proline, to be possibly damaging to the protein structure. This 8 kb region 
also includes coding sequence for aspartic acid 385, one of the three amino acids that 
make up the putative active site of the enzyme [190], such that the proline substitution 
may alter the active site’s physical conformation. Supporting the potential functional 
effect of rs11564620, this polymorphism is associated with 11-DTXB2 levels in healthy 
individuals (p=0.02; Figure 5.6), with proline allele carriers having elevated thromboxane 
metabolite levels, compared to threonine homozygotes.  
PLA2G4C encodes cytosolic phospholipase A2 gamma, which hydrolizes 
phospholipids from the cellular membrane to free arachidonic acid, from which 
prostaglandins, including prostaglandins D, E, F, I2 (also known as prostacyclin), and 
thromboxane A2 are generated. Prostaglandins likely play an important role in 
parturition. Pharmacologically, prostaglandins are used to induce abortion, for cervical 
ripening and labor induction, and drugs inhibiting prostaglandin synthesis are successful 
in preventing preterm labor [191]. Levels of prostaglandins, including thromboxane A2, 
are elevated in pregnant compared to non-pregnant women, and in later (36 weeks) 
compared to earlier (20, 30 weeks) gestation [192], suggesting a link between 
prostaglandin abundance and parturition timing. Prostaglandins may facilitate labor by 
several mechanisms. These hormones are known uterotonic agents and also promote 
luteolysis and the onset of labor in species that exhibit progesterone withdrawal prior to 
birth [193]. Prostaglandins may also facilitate delivery by affecting placenta function, 
since thromboxane A2 induces platelet aggregation and acts as a vasoconstrictor [192]. 
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 Hence, higher prostaglandin levels than expected may initiate parturition prematurely and 
lead to preterm delivery.  
The PLA2G4C enzyme is the only cytosolic phospholipase A2 family member 
that is constitutively associated with the cellular membrane, the site of prostaglandin 
synthesis, rather than translocating to the membrane in response to calcium signaling 
[186]. Hence, dysregulation of PLA2G4C may alter prostaglandins levels independent of 
other parturition signals, such as oxytocin [194], that act via intracellular calcium 
signaling. For example, rs11564620 may contribute to a conformational change in the 
enzyme’s active site, rendering it more active than usual and leading to increased 
synthesis of prostaglandins, as demonstrated by our observation of higher levels of 
thromboxane A2 in minor allele carriers for this polymorphism. Moreover, multiple 
splice isoforms of PLA2G4C exist, differing in transcript length, presence of certain 
exons and overlapping exons with different boundaries (AceView, NCBI, 
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/). As a result, variation in 
PLA2G4C may contribute to differences in tissue-specific expression or relative 
abundance of various PLA2G4C isoforms, potentially altering function. Further study of 
the region encompassing these SNPs, including the genomic element of interest, is 
needed to examine the mechanism by which variation in PLA2G4C influences birth 
timing. 
Specialization within multi-gene families, like the large phospholipase A2 gene 
family, can create individualized functions among paralogous genes. For example, 
PLA2G4C has a continuous association with the cellular membrane, unlike other 
phospholipase A2 genes, potentially differentiating its role in prostaglandin synthesis 
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 from those of other family members. Genomic variation, such as the element insertion 
observed in PLA2G4C, may contribute to gene specialization, as demonstrated by 
divergence in PLA2G4C expression patterns in humans versus mice, who lack the 
element insertion and express PLA2G4C only in ovary and oocytes [195]. Specialized 
genes are potentially better therapeutic targets than gene products with multiple roles 
within cell, since pharmaceutically targeting such genes may lead to fewer side effects. 
As a result, PLA2G4C may be a useful target for designing novel therapies to prolong 
pregnancy and reduce the incidence of PTB. 
 
Material and Methods 
Genomic alignments to investigate evolutionary history of PLA2G4C. Noting 
the deletion of PLA2G4C reported in the Taurine Cattle genome [187] contrasted with its 
presence in the 17-way MultiZ alignments [165] we used to identify the gene as rapidly 
evolving (analysis conducted Spring 2007 and presented in [136]), we examined the 
history of this region in greater depth. We extracted sequence surrounding the 130 bp 
highly conserved noncoding element (human chromosome 19: 48,560,500 -48,560,630; 
hg19 genome build) which largely contributed to our designation of PLA2G4C as rapid 
evolving along the human lineage. A BLASTN search of the element revealed highly 
identical conserved noncoding elements on human chromosomes 1 (87% identity) and 2 
(85% identity) (Figure 5.1B). We compared the human chromosome 19 and chromosome 
1 sequences to 31 eutherian mammalian genomes using Ensembl Genomic alignments 
(accessed September 2009), and ClustalW alignment, and to specific primate genomes 
using BLASTN searches of human, chimpanzee, gorilla, orangutan, macaque, and 
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 bushbaby genomes (accessed September 2009). We then reconstructed history of the 
element by creating phylogenies using the neighbor joining with Kimura distances and 
maximum likelihood methods with sequences homologous to the human chromosome 19 
element (Figures 5.2) and coding sequences homologous to human PLA2G4C (Figure 
5.3). 
Human subjects. Study subjects were enrolled for genetic analysis by methods 
approved by Institutional Review Boards/Ethics Committees at each participating 
institution. Informed consent was obtained for all participants. Mothers with PTB were 
included if the birth was spontaneous (non-iatrogenic), singleton, had no obvious 
precipitating stimulus (trauma, infection, drug use), and was less than 37 weeks (Yale 
University; New York University) or 36 weeks (University of Helsinki; University of 
Oulu; Centennial Hospital, Nashville, TN) of completed gestation. Control mothers were 
included if they delivered two or more children at 37 weeks or later spontaneously. 
Healthy volunteers were recruited at Vanderbilt University for studies of prostaglandin 
metabolism. DNA from blood or saliva was prepared by standard methods. 
Race/ethnicity was assigned by self-report. All specimens were linked with demographic 
and medical data abstracted from maternal/neonatal records. DNA from blood or saliva 
was prepared by standard methods.  
Prostaglandin metabolite levels. For individuals enrolled in the prostaglandin 
study, urine was collected by standard methods. Levels of the urinary metabolites of 
prostaglandin E (PGE), prostaglandin I (PGI) and thromboxane (11-DTXB2) were 
quantified by mass spectrometry and normalized to creatinine levels, an indicator of renal 
function, in 44 healthy control individuals of Black, Hispanic or White race (median age 
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 29, 60% male, 77% White).  
Genotyping. We genotyped 14 SNPs spanning the PLA2G4C gene region (Table 
5.1) on human chromosome 19 in cohorts of US Hispanics (n= 73 preterm, 292 control 
mothers), US Whites (n= 147 preterm, 157 control mothers) and US Blacks (n= 79 
preterm, 166 control mothers). For SNP selection, data from the HapMap CEU 
population was examined in the Haploview program [177], using tagger and haplotype 
block functions, to identify regions of high LD. We selected 1 SNP per haplotype block, 
defined using the D’ confidence interval method [178], having the highest minor allele 
frequency (MAF) in the CEU population for genotyping. We also included coding SNPs 
and SNPs to improve coverage of conserved elements contributing to the gene’s 
designation as “rapidly evolving.” This selection scheme resulted in approximately 35% 
coverage of the gene region at r
2≥0.8. SNPs showing evidence of association in one or 
more cohort (p<0.01; n=4) were then genotyped in healthy individuals on whom data on 
their concentrations of several prostaglandin metabolites was available to examine 
potential functional effects of the variants. All SNPs were genotyped using the Sequenom 
iPLEX massARRAY technology (Sequenom, San Diego, CA).  
Data Analysis. Data cleaning and analysis was performed with Whole-genome 
Association Study Pipeline (WASP) [174] and PLINK [175]. We excluded individuals 
based on genotyping quality (<90% call rate) and possible cryptic relatedness and SNPs 
based on the following criteria: not in Hardy-Weinberg Equilibrium in controls (p<0.001 
2
 test), <90% genotype call rate, MAF<0.01). Linkage disequilibrium among SNPs 
tested was determined using the Haploview program [177]. 
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 Our analysis considered PTB affection status (i.e. delivery <37 weeks) as a binary 
trait, comparing frequencies between case and control groups of alleles and genotypes by 
2 test. Sliding windows of 2,3 and 4 SNP haplotypes also were compared between cases 
and controls [175]. Meta-analysis of data for significant SNPs was done using the 
Mantel-Haenszel method. We corrected for multiple testing using the simpleM method 
[176], which estimates the number of independent tests, given the LD relationships 
among SNPs, used to obtain a Bonferroni-corrected critical value. 
To test the potential functional effect of associated PLA2G4C variants on 
prostaglandin metabolism, we examined the levels of PGE, PGI, and 11-DTXB2, 
standardized to normal distributions ( =0, =1), as quantitative traits. A Wald test was 
performed to compare the mean phenotype between different allele or genotype classes 
for associated SNPs. We also tested whether rs11564620 risk-allele carriers had higher 
prostaglandin levels than noncarriers, by comparing the 11-DTXB2 value distribution 
among genotype classes with box plots and one-sided Wilcoxon nonparametric test 
performed in R [158]. 
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Figure 5.2: Phylogeny with sequences homologous to human chromosomes 19 noncoding element. 
 
Species name followed by a number indicates from which chromosome the sequence is derived or by a 
letter indicates that multiple copies homologous to the human chromosome 19 noncoding element were 
identified for that species. Sequences from lower primates and other mammalian species are more similar 
to higher primate sequences orthologous to human chromosome 1noncoding element (indicated in blue) 
than sequences orthologous to human chromosome 19 noncoding element (indicated in red). A duplication 
of chromosome 1 noncoding element to chromosome 19 likely occurred before the last common ancestor 
between apes and macaque. 
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Figure 5.3: Phylogeny with coding sequences homologous to human PLA2G4C. 
 
Species name followed by a letter indicates that multiple copies homologous to human PLA2G4C were 
identified for that species. Phylogenetic tree of coding sequences follows expected relationships between 
species, suggesting that the duplication event of chromosome 1sequence to chromosome 19 did not include 
coding sequence. 
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Figure 5.5: Linkage Disequilibrium among SNPs tested in PLA2G4C. 
 
 
 
 
Linkage disequilibrium among SNPs tested in PLA2G4C for US Hispanics (A), US 
Whites (B), and US Blacks (C). 
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Figure 5.6: Comparison of thromboxane metabolite levels among rs11564620 
genotype classes in healthy control population. 
 
 
 
Median thromboxane metabolite levels are significantly greater among risk-allele 
carriers, by Wilcoxon one-sided test. 
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Table 5.3: Case-control association results for 2, 3 and 4 SNP haplotypes in the 
PLA2G4C gene region tested across 3 independent US populations. 
 
 US Hispanics US White US Blacks 
p-value p-value p-value 
2-SNP Haplotypes 
rs11564650-rs8110925 9.54x10
-3 a 0.10 0.59 
rs8110925-rs2307276 6.98x10
-5 b 0.98 0.24 
rs2307276-rs1366442 8.82x10
-3 0.64 0.64 
rs1366442-rs11564620 0.04 0.03 0.90 
rs11564620-rs11668556 0.25 0.03 0.63 
rs11668556-rs1653554 0.49 0.82 0.42 
rs1653554-rs2307279 NA
c
 0.47 0.68 
3-SNP Haplotypes 
rs11564650-rs8110925-rs2307276 9.60x10
-4 b 0.19 0.39 
rs8110925-rs2307276-rs1366442 5.79x10
-4 b
 0.84 0.50 
rs2307276-rs1366442-rs11564620 0.03 0.06 0.79 
rs1366442-rs11564620-rs11668556 0.06 0.08 0.92 
rs11564620-rs11668556-rs1653554 0.31 0.09 0.30 
rs11668556-rs1653554-rs2307279 NA
c
 0.91 0.89 
4-SNP Haplotypes 
rs11564650-rs8110925-rs2307276-rs1366442 3.26x10
-3
 0.24 0.67 
rs8110925-rs2307276-rs1366442-rs11564620 1.25x10
-3 b 0.13 0.46 
rs2307276-rs1366442-rs11564620-
rs11668556 
0.08 0.17 0.93 
rs1366442-rs11564620-rs11668556-
rs1653554 
0.08 0.25 0.47 
rs11564620-rs11668556-rs1653554-
rs2307279 
NA
c
 0.11 0.54 
 
a
Bolded numbers indicate p-value <0.05. 
b
Haplotype significant correcting for 18 comparisons (p< 2.78x10
-3
). 
c 
One or more marker excluded for failing one or more of the following measures: Hardy-
Weinberg Equilibrium failure in controls p<0.001, <90% call rate, MAF<0.01. 
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 Chapter 6: Conclusions and future directions 
State of preterm birth genetics prior to this work 
Despite the important public health consequences of PTB [3; 4], determinants of 
human parturition remain largely uncharacterized, making prediction and prevention of 
PTB difficult. Genetic studies are one way in which we can attempt to better understand 
this disorder. Prior to this work, little work had been done to characterize genetic 
influences on PTB comprehensively. For example, while a variety of evidence suggested 
that PTB was influenced by complex genetic and environmental factors, no study had 
tested genetic and non-genetic models to support this notion explicitly. Additionally, few 
specific genes were associated with PTB at the initiation of this work. Importantly, few 
studies examined genes outside of the inflammation and infection pathways, limiting the 
potential of genetic studies to identify new biology. As a result, we began this work to 
describe genetic influences on PTB in greater depth and identify novel genes associated 
with this disorder.  
Dissertation specific aims 
Because the etiology of PTB is complex and likely involves both genetic and 
environmental risk factors, developing a model for the genetic influences on PTB may 
facilitate gene discovery. As little work had been done to systematically identify a genetic 
model for PTB,we used sibling risk estimates and segregation analyses to identify one. 
We examined two standard measures of familial aggregation, the sibling risk 
ratio, s, and the sibling-sibling odds ratio (sib-sib OR) to test whether siblings of 
preterm infants were at higher risk for preterm delivery themselves. Risk to siblings of an 
affected individual was elevated above the population prevalence of a given disorder, as 
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 indicated by S ( S (95% CI): 4.3 (4.0-4.6)), and above that of siblings of unaffected 
individuals, as indicated by the sib-sib OR (sib-sib OR adjusted for known risk factors 
(95% CI): 4.2 (3.9-4.5)). These results suggest that the PTB aggregates in families, which 
may be explained in part by genetics. 
Additionally, we performed segregation analyses to identify the best fitting 
genetic model for gestational age, a quantitative proxy for PTB. We performed 
segregation analysis for gestational age as a quantitative trait either attributed to the 
infant, infant’s gestational age, or to the mother, by averaging the gestational ages at 
which her children were delivered, using 96 multiplex preterm families. Additionally, as 
pregnancies in which either the mother [10; 13] or father [6; 7] is Black are at increased 
risk for preterm delivery, we performed segregation analysis for each phenotype in the 
total sample, as well as stratified by Black and White race, to test for heterogeneity 
between these two groups. Results from our segregation analyses lend further support to a 
genetic component contributing to birth timing since sporadic (i.e. no familial 
resemblance) and nontransmission (i.e. environmental factors alone contribute to 
gestational age) models are strongly rejected. Moreover, these results corroborate the 
conceptualization of PTB as a complex diseases are influenced by a variety of factors, 
none necessary and sufficient to cause the disorder itself, in contrast to Mendelian 
disorders in which alterations of a single gene can lead to disease. Analyses of gestational 
age attributed to the infant support a model in which mother’s genome and/or maternally-
inherited genes acting in the fetus are largely responsible for birth timing, with a smaller 
contribution from the paternally-inherited alleles in the fetal genome. Additionally, 
results from a heterogeneity 
2
 test comparing race-stratified analyses suggest that 
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 genetic influences on birth timing may differ between Blacks and Whites. Overall, as 
multiple genes in the mother’s genome may explain the bulk of genetic influences on 
birth timing and heterogeneity exists among racial groups, future studies to identify 
specific genes influencing PTB perhaps will be most fruitful by using large scale studies 
of mothers’ genomes and by considering racial composition of the study samples 
carefully in their statistical analysis. 
We also aimed to discover specific genes associated with PTB using an a priori 
method, a screen of genes selected based on an evolutionary-motivated filter, rather than 
predicted parturition physiology. Because humans are born developmentally less mature 
than other mammals [124; 125], birth timing mechanisms may differ between humans 
and model organisms that have been typically studied [126]; as a result,we screened 150 
genes, selected because of their rapid evolution along the human lineage, compared to 
other mammalian species, rather than our current understanding of parturition. An initial 
screen of over 8000 SNPs in 165 preterm and 163 Finnish mothers identified an 
enrichment of variants in FSHR associated with PTB and prompted further study of the 
gene. Additionally, the phospholipase gene, PLA2G4C, was examined in greater depth, as 
it was identified as the gene with the most statistically significant evidence for rapid 
evolution that was also included in a list of PTB candidate genes [134]. Several variants 
in PLA2G4C showed potential association and were considered for follow-up analysis. 
To validate our initial findings,we examined 74 variants showing moderate levels 
of association in Finnish mothers in three additional US populations. Three SNPs in 
PLA2G4C and one SNP in FSHR were statistically significant after correcting for the 
number of independent tests performed for each gene. Meta-analysis p-values for these 
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 variants were also significant correcting for multiple comparisons, supporting the role of 
PLA2G4C and FSHR in PTB.  
Additional work to identify variants in these genes with functional effects was 
also initiated. First, we compared metabolite levels of three important downstream targets 
of PLA2G4C among genotype classes for significantly associated SNPs in healthy 
controls. The nonsynonymous SNP rs11564620 (Thr360Pro) was associated with levels 
of the prostaglandin thromboxane, suggesting this variant may affect PLA2G4C activity. 
Secondly, because the robustly associated SNP in FSHR was intronic and unlikely to 
have a direct effect on function, we initiated sequencing of coding and highly conserved 
non-coding regions in the gene in Finnish preterm and control mothers to identify 
additional variants, which may have functional effects. 
Together, these experiments better characterize the nature of genetic influences on 
PTB and provide evidence for novel genes involved in this disorder. 
Future directions 
While two novel genes have been associated with PTB as the result of this 
dissertation project, additional work will be needed to dissect the genetic underpinnings 
of PTB robustly and apply this new knowledge towards improved patient care. Such 
work may include identifying additional variants in FSHR and PLA2G4C and 
determining the ability of highly associated SNPs to predict PTB. Because this work has 
examined only common variants, investigating rare variants may be particularly 
enlightening. Rare variants tend to have stronger effects on phenotype and may underlie 
associations attributed to common variants [196]. A single rare variant or a combination 
of multiple rare variants in FSHR, PLA2G4C or other genes may contribute to PTB risk, 
as has been shown for other common diseases, like type 1 diabetes and obesity [197]; 
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 thus, whole exome or targeted sequencing may identify risk-promoting variants in FSHR 
and PLA2G4C, and additional genes involved in PTB. For genetic variants of interest, 
gravid women may be followed prospectively to compare the pregnancy histories 
between women with high risk and low risk genotypes. Further study of the proteins 
encoded by FSHR and PLA2G4C will also be important to understand the biological 
mechanism by which these genes influence PTB risk. In addition to extensions of our 
work on PTB, the evolutionarily-motivated approach we used to identify FSHR and 
PLA2G4C also may be applied to other traits that differ between humans and other 
mammalian species, such as neurological and language-related traits, to assist gene 
discovery.  
Alternative approaches may also be used to identify additional genes associated 
with PTB. Unbiased genome-wide screens, such as the case-control screen conducted on 
a Danish cohort as part of the National Institutes of Health Gene Environment 
Association Studies (GENEVA) program, may identify novel genes and pathways for 
birth timing, as for other complex disorders like type 2 diabetes [198]. Additionally, non-
additive genetic effects, such as copy number or structural variation, may be important 
avenues for future research. Moreover, because complex disorders likely depend on a 
number of interacting factors, including genetic, epigenetic and environmental risk 
factors [31], some polymorphisms may only increase risk in the context of other genetic 
polymorphisms or certain environmental factors; as a result, considering polymorphisms 
in multiple genes or gene-environment interactions may increase our power to detect 
genetic effects. Investigators have applied this approach in candidate gene studies of 
PTB, including two studies of IL6 found association with the gene and disorder only in 
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 the presence of bacterial vaginosis [35] or microbial invasion of intra-amniotic cavity 
[37]. Similarly, a study found interactive effects for TNF x IL6 x IL6R, but no main 
effects for any of the genes [34]. As a result, testing for gene-gene and gene-environment 
interactions globally may improve our ability to discover novel PTB genes. Such 
approaches may enable investigators to identify novel genes and pathways involved in 
birth timing with important clinical applications. 
Overall, future studies to understand genetic influences on PTB likely will include 
identifying additional genes and specific variants associated with risk and followed with 
work to examine biological mechanisms for their involvement in birth timing. In the 
same way that the study of other complex disorders has affected the field of PTB 
genetics, the evolutionarily-motivated approach for prioritizing genes for inclusion in 
association studies we used to identify FSHR and PLA2G4C may be extended to other 
complex traits. 
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• Girls on the Run International, Nashville, Tennessee, 2009-2010 
o Coach and running buddy 
o Fundraising through SoleMates program 
• Team in Training, The Leukemia & Lymphoma Society (LLS), Nashville, Tennessee, 2009 
o Team member- raised $1835 while training for the 2009 Country Music Half Marathon 
o Team captain - fundraising and training support for new team members 
• Restore St. Louis, Saint Louis, Missouri, 2007-2008 
o Tutor, Firm Foundations Tutoring Program  
o Volunteer and crew leader, Work Day ministry 
 
• Endurance running 
Hobbies and personal interests 
o completed 2 half marathons to date, training for full marathon in 2010 
• Ballroom dancing  
o  Bronze level dancer 
• Member of Toastmasters International, 2007-2008 
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